Arresting Tumor Cell Proliferation and Inhibition of Akt Pathway via the Use of Multikinase Inhibitor Sorafenib forthe Treatment of Glioblastoma

By

Md. Ismail Raju
17346042

A thesis submitted to the Department of Pharmacy in partial fulfillment of the requirements for the degree of
Bachelor of Pharmacy (Hons.)

School of Pharmacy
Brac University
March 2022

Declaration

It is hereby declared that

1. The thesis submitted is my/our original work while completing my degree at Brac University.
2. The thesis does not contain material previously published or written by a third party, except where this is appropriately cited through full and accurate referencing.
3. The thesis does not contain material that has been accepted or submitted, for any other degree or diploma at a university or other institution.
4. I/We have acknowledged all main sources of help.

Student's Full Name & Signature:

Md. Ismail Raju

Md. Ismail Raju
17346042

Approval

Theproject titled “Arresting Tumor Cell proliferation and Inhibition of AKT Pathway Via The Use Of Multikinase Inhibito Sorafenib For The Treatment Of Glioblastoma” submitted by MD. Ismail Raju(ID-17346042) of Summer, 2017 has bee accepted as satisfactory in partial fulfillment of the requirement for the degree of Bachelors of Pharmacy on [09-03-2022

Examining Committee:

Supervisor:
(Member)

Tanvir Kabir
_____
MD. Tanvir Kabir
Senior lecturer, School of Pharmacy
Brac University

Program Coordinator:
(Member)

_____
Namara Mariam Chowdhury
Lecturer, School of Pharmacy
Brac University

Deputy Chair:
(Member)

_____
Dr. Hasina Yasmin
Professor and Deputy Chair, School of Pharmacy
Brac University

Departmental Head:
(Dean)

_____
Dr.Eva Rahman Kabir
Professor and Dean, School of Pharmacy
Brac University

Ethics Statement

This paper is done by my work and under the supervision of Md. Tanvir Kabir, SeniorLecturer, School of Pharmacy, BracUniversity, and I have given proper credit fromwhere I have used ideas and information. This thesis paper is submitted for the partialfulfillment of the requirements for the degree of Bachelor of Pharmacy (Honors) so it doesnot involve any human or animal trial. No animals were used or harmed in this project.

Abstract

Glioblastoma multiforme is one of the common forms of brain cancer found worldwide, and treatment options are limited for this deadly disease. Various targeted treatments are being investigated, but no breakthroughs have yet been made. One of the most promising aspects of the glioblastoma treatment is the restriction of the intracellular signal transduction,also known asthe strain transformingpathway, and recently it has become the hotspot of brain cancer research. Sorafenib is a model drug that has shown signs of success in preclinical trials. Sorafenib, which is a multi-kinase inhibitor, induces growth arrest and apoptosis of human glioblastoma cells through the dephosphorylation of signal transducers and activators of transcription 3 and thus poses a promising aspect in developing a potential treatment of glioblastoma. This thesis report focuses on the use of sorafenib for the Protein kinase B (AKT) inhibition as a potential cure for glioblastoma.

Keywords: Glioblastoma; AKT inhibition pathway; Sorafenib; Tumor cell proliferation; Dephosphorylation.

Dedication

Dedicated to my parents

Acknowledgments

It is a pleasure to express my deep sense of thanks and gratitude to my supervisor, Md. Tanvir Kabir (Senior Lecturer, Department of Pharmacy, Brac University) for allowing me to work on this project. His prompt inspiration at every stage of my project work and timely suggestion with kindness, dedication, scientific approach, constant guidance, collaboration, and enthusiasm make me enable to finalize the project.

I owe a deep sense of gratitude to our honorable chairperson, Professor Dr. Eva Rahman Kabir (Chairperson, Department of Pharmacy, Brac University) whose support, encouragement, scholarly advice were the sustaining factors in carrying out the project successfully.

Also, I take this opportunity to express my gratitude to all the faculty members and lab officers for their help and support.

Last but not the least, I would like to express my greatest regards to my parents for their co-operation, continuous support, unconditional love throughout my life.

Table of Contents

List of Figures:

List of Acronyms

GBM: Glioblastoma

AKT: Protein Kinase B

PI3K: Phosphatidylinositol 3-kinase

RTK: Receptor Tyrosine Kinase

GPCR: G-protein kinase receptor

PTK6: Protein tyrosine kinase 6

EGFR: Epidermal Growth Factor Receptor

mTOR: Mammalian target of rapamycin

MAPK: Mitogen-Activated Protein Kinase

GTP: Guanosine triphosphate

TERT: Telomerase Reverse Transcriptase

IRS-1: Insulin Receptor Substrate 1

Chapter 1:

Introduction

Glioblastoma multiforme is a fatal type of brain cancer that grows aggressively. GBM can develop in the brain or spinal cord (De Vries et al., 2012; Hu et al., 2017). Gliomas are classified into Four categories:grade I, grade II, grade III, and grade IV where GBM is referred to as grade IV astrocytoma(cancer that occurs in the brain or spinal cord) (Fenstermaker et al., 2016; Phuphanich et al., 2013; Song et al., 2020). It attacks the tissues of the brain which is near to the tumor growth and in most cases; it does not spread to other parts of the body (F. F. Lang et al., 2018; Sengupta et al., 2012). GBM develops from low-gradeastrocytoma,which can arise in the brain from nowhere. GBMis mostly found in the cerebral hemisphere, especially in the frontal and temporal lobes. It is rarely possible to cure or treat GBM. Joy et al., 2016). The prognosis of the disease depends on the stage at which it is diagnosed. The reasons behind the growth of gliomas are still unknown, despiteall the advancements in therapy (Kaley et al., 2019; Steelman et al., 2010). This disease is not passed on from generation to generation. Removal of the tumor,along with routine radiation for day to day and oral chemotherapeutic medicines for six and a half weeks, and then a six-month course of oral chemotherapy given five days a month, is the standard of care for a GBM patient (Álvarez-Garcia et al., 2019; Itoh &Ornitz, 2004).

To begin, the neurosurgeon will eliminate as much from the tumor as feasible, then medicated wafer-like chips may be implanted directly into the brain (P. H. Huang et al., 2009; Manning &Cantley, 2007; Wenger et al., 2015). These chips disintegrate naturally and slowly and then deliver chemotherapeutic medicines into the tumor region (Amirian et al., 2016, 2016; A. C. Tan et al., 2020). In 2013, the FDA allowedtemozolomide(TMZ), a chemotherapeutic medication that is frequently used for curing GBM and other advanced brain tumors (Baba et al., 2021; L. P. Liu

et al., 2012; Seliger et al., 2020). The medication is given as a tablet and acts by reducing tumor development by inhibiting the production of DNA among the tumor cells (Larson et al., 2014; Z. Z. Yang et al., 2004; C. Z. Zhang et al., 2015). Radiation can kill more abnormally growing cells and treat cancers for individuals who are unable to undergo surgery (Cohen et al., 2013; Shiojima& Walsh, 2002).

The present procedure of GBM therapy is successful, with more patients living two, three, four, or even five years after diagnosis (Grossman et al., 2009; Scartoni et al., 2020; Zhai et al., 2014). Unfortunately, this treatment is notthe end, which means it does not eliminate all tumor cells. That is why we are trying so hard to come up with new therapeutic options (Alexander et al., 2018; Sheng et al., 2010). Existing therapies have had varying results to improve overall survival (Bobustuc et al., 2010; Hasselbalch et al., 2010; Sareddy et al., 2013). As a result, finding and understanding the essential molecule(s) responsible for GBM's malignant nature will lead to novel treatment targets (Davies et al., 2013; Happold et al., 2016; Stupp et al., 2017). The existence of the blood-brain barrier (BBB), which restricts concentrated medicines that may reach the tumor site, create problems in treating gliomas (Hegi et al., 2011; Wei et al., 2008; F. Yang et al., 2010). Numerous potential therapieshave been proven to penetrate the BBB, with promising pre-clinical results (Guo et al., 2009; Jo et al., 2018; X. Liu et al., 2016). The inhibition of the AKT pathway is showing promising results in the preclinical tests being done with the use of different drugs. Of them, sorafenib is more likely to be the most successful in the long run (Hegi et al., 2011; Unteroberdörster et al., 2021; F. Yang et al., 2010).

GBM is the furthermost broadly known & commanding rudimentary frontal cortical cancer type (Cui et al., 2016; Johnson et al., 2016). The measures include degradation and uncontrollable endothelial growth of cells, attaining the most crucial feature of grade IV cancer. Frontal cortex

growth of the brain in GBM matches the definition of grade IV astrocytoma by the World Health Organization (WHO) (Benitez et al., 2017; Beug et al., 2017; J. L. Huang et al., 2017). At the starting period of GBM without histological/clinical confirmation of a lesser grade lesion, GBM can develop as a more fundamental malignant form (approximately 90% of GBM patients), or as a helper ofglioma developing from low-grade gliomas high-grade gliomas, such as a diffuse astrocytoma or anaplastic astrocytoma (Benitez et al., 2018; Beug et al., 2018; Kang et al., 2017). The distinction between fundamental and assistant GBMsisuncertain inthe histopathological form where it is difficult to identify; helper GBMs are characteristically more active than the fundamental GBM.

The Cancer Genome Atlas (TCGA) published a comprehensive review of two hundred and sixteen GBM development tests in 2010, thoroughly illustrating the GBM genomic landscape (P. Wang et al., 2021; Xie et al., 2021; R. Yang et al., 2020). A handful of significant genetic alterations were noticed in that review. Upgrades and modifications to the Epidermal Growth Factor Receptor (EGFR), Crossing out/changes in Phosphatase and Tensin homolog (PTEN), and CDKN2Ap16INK4a were seen regularlyin cancers(Maier et al., 2021; R. Yang et al., 2021). However, in basic GBM, changes in isocitrate Dehydrogenase 12 (IDH1/2) or Tumor protein 53 (TP53) were common, but in helper GBM, changes in isocitrate Dehydrogenase 12 (IDH1/2) or Tumor protein 53 (TP53) were not common. As the alteration occurred, IDH1 was also identified as the most powerful demonstrative sub-nuclear marker of assistant GBM. Such markers help the assistant glioma to grow as a high-grade glioma in the brain. (J. Wu et al., 2021; Zhu et al., 2021). The powerful treatment of GBM is still being investigated, andhowever, to be found.

This review focuses on the potential of sorafenib within the inhibition of the AKT pathway to treatGBM(Ahmadov et al., 2021; Dadras et al., 2021; W.-B. Yang et al., 2021). The rest part of

this review will deliver basic experiences ofthe current treatment situation of theGBM and it willto provide an outline of the pathogenesis of GBM multiforme broadly (Dong et al., 2018; H. Li et al., 2021; Pibuel et al., 2021). **Figure 1** shows the histological images on the MRI scans and the developmental phases of glioma



Figure 1: *Glioblastomas histological image on MRI (Benitez et al., 2018; Beug et al., 2018)*

1.1 Current treatment procedures of glioblastoma

After the diagnosis of the tumor, as per the stage of the glioma found in the examinations required treatment processes take place. If the surgery is required for the patient then after doing the operation the complex field radiotherapy takes place incorporated with sixassistancesofTMZchemotherapyfor the standard care of the Bigger portion of patients with late dismembered GBM (Couturier et al., 2020; Obara et al., 2020; Yee et al., 2020). In any case, for advancement treating areas, no other recuperating intercession has been appeared to draw out all the things considered diligence with patient safety (Gregory et al., 2020; A. Schuster et al., 2020; Y. Wu et al., 2020). A small degree of patients with limited complications have advised an operation or re-enlightenment, however,this process has not been appeared to bring out all the infected cells from the glioma (Agliardi et al., 2021; R. Fang et al., 2021; Sachamitr et al., 2021). Along with the radiotherapy one more course of alkylating chemotherapy, who's most part is nitrosourea compound such as lomustine which isbroadly utilized in intercession at reiterate of the glioma and other than Comprises the control arm in late randomized preliminaries in excess GBM (Brooks et al., 2021; Herviou et al., 2021; Yeini et al., 2021). In any case, not one or the other lomustine nor a few other key Treatment or advancement treating areas (Stupp et al., 2012) have been appeared to be way better than immune therapy treatment or best reliable thought in a randomized principle. **Figure 2** shows the therapeutic targets of the treatment of glioma outlines the immunotherapeutic aspects of GBM.



Figure 2: *Targets to treat glioblastoma therapeutically (Lu et al., 2021; F. Yang et al., 2021)*

1.1.1 Treatment strategies for glioblastoma

Most patients suffering from GBM will hold to a standard treatment process after cautious surgery. Seven days to about a month and a half, similarly to oral TMZ step by step (Barekatain et al., 2021; H. Huang et al., 2021; Nguyen et al., 2021). Most patients will show symptoms inside 6.9 monthsat the early age of finding. New trained professionals or treatment association systems are commonly at the first attempt to avoid redundant strategies where there are some impactful treatment options (Kim et al., 2021; Lefevre et al., 2021; Z. Zhang et al., 2021). In patients with either clinical or radiological development, diverse treatment strategies have been assessed to treat the disease (Happold et al., 2016; Koga et al., 2012; Puli et al., 2010). As a portion of the multidisciplinary

treatment processesfirst of all comes the reviewing of the gliomas, next comes the choices of operation for picked patients, despite everything that in like way qualified, essential chemotherapy, and clinical preliminary venture (Cantanhede& De Oliveira, 2017; kalhori et al., 2020). Most patients are not capable of re-surgery so thereby clinical starter participation chemotherapy,radiotherapy, immunotherapy are the most excellent choices. Chemotherapy options for high-grade tumors combine carboplatin, irinotecan, Carmustine (BCNU), etoposide,procarbazine,lomustine, and Vincristine (PCV) blend (Brenner et al., 2021; Liang et al., 2021; Maeyama et al., 2021). Bracing starter information from clinical organizes one or two essential steps are taken such as, to stop the progress of EGFR reprobates, the mammalian objective of rapamycin (mTOR) inhibitors,and other allotted inhibition Peaks are being observed to hinder the growth of the tumor (Villano et al., 2009).Further, test approaches Utilizing convection updated development, undifferentiated cell treatment, immunotherapy, and quality treatment dependent upon advancing influenced therapeutic exposures which give Vitality with confirmation for what's to come (Carvalho et al., 2021; Chojak et al., 2021; Hirono et al., 2021).

1.1.2 Limitations of the available treatment procedures

There are two or three processes like chemotherapy, radiotherapy, surgerywhich are followed in treating GBM.The different treatment system is taken after for different kind of patients with glioma (Mesic et al., 2021; Shah et al., 2021; Wen et al., 2021). With the headway of cutting-edge sequencing and the concentrated nuclear coordinating of GBM, many imperative focuses have been seen and distinctive methodologies have been investigated for GBM Drugs. IDH changes, which is present in large amount in discretionary GBM, solidify both a misfortune and pick up of protein work (Cohen et al., 2013). There is a momentous combination of 2-hydroxyglutarate (2-HG), which could be a driver of tumor genesis (Killock, 2016; W. Kim and Liau, 2012). A few

IDH inhibitors are inevitably being Surveyed in clinical starters, counting AG-120 (mIDH1 inhibitor), AG881 (flawed IDH inhibitor), FT-21-2 (mIDH1 inhibitor), and IDH305 (an IDH1 (R132H inhibitor). EGFR inhibitors likegefitinib, Erlotinib, and afatinib have shown a steadiness advantage in gliomas(Sepúlveda-Sánchez et al., 2017), for their activities they have been valuable in numerous dangerous turns of situation a patient can experience. In GBMinner expansion has been called a street hindrance for the sole objective-type process; thusly, endeavors have been made to survey small beta-blockers with distinctive destinations like Regorafenib which blocks the activities of protein kinases (Binder et al., 2021; Tanaka et al., 2021).

An organized II Preparatory appeared an extension inlarge consistency for eccentric GBM (Lombardi et al., 2019), whereas we can see one or two who are surveying regorafenib with different treatment limits of late and Discontinuous GBM (Alexander et al., 2018) DepatuxizumabMafodotin, notwithstanding called ABT-414, is an investigational threatening to EGFR monoclonal Neutralizer which sedate thestructure of the tumor. ABT-414 shinesa light on the progression cells by accomplice the counter microtubule where as Monomethyl auristatin F, with a neutralizer made against EGFR. Despite being different Individual Interiorarrangements, EGFR increase had a certified response, and usually being checked on in an organized II major with ABT-414 and TMZ in dismal EGFR which further creates GBM. Monoclonal antibodies address one more lesson that has been utilized considering almost their tall state of mind and proclivity to their targets. Bevacizumab, which ties to VEGF, controlling the change of veins, Gotten sped up FDA bolster within the wake of interfacing with organize I/II essentials, however, whereas organizing III examinations Appeared a few extended out of headway free constancy, there was no seen by and expansive relentlessness advantage (Gilbert et al., 2014) (Hamza et al., 2014).

Cetuximab (EGFR monoclonal neutralizer), in like way disregard to appear tirelessness benefits in organizing II starters (Neyns et al., 2009) (Hasselbalch et al., 2010), whereas monoclonal immunizer treatment framework lacks unsafe advancement. Because of their measure and limited cutoff in the crossing point of the blood intellect hindrance. Since the achievement stores up in 2005 (Stupp et al., 2005), TMZ is used most in line treatment taking after Restorative methodology and radiotherapy. This randomized clinical assessment appeared a fundamental assurance advantage with the headway to radiotherapy. Regardless, some of the glioma patients do not respond to this treatment process known as the Stupp appear, whereas other patients may, at last, Appear ordinary or picked up chemo resistance, over the long pull fulfilling peril rehash (S. Y. Lee, 2016). A positive Prognostic pointer for TMZ-based chemotherapy is not settled withGBM but was related to MGMT quality methylation (Stupp et al., 2005). The Researchers, exploring elective plans of TMZ treatment have not found any capability in Result between their treatments appears, however they saw that MGMT promoting master methylation was a prognostic marker within the TMZ treatment to monotonous glioma patients (Weller et al., 2015).

DNA alkylating Masters, known as nitrosoureas counting lomustine (CCNU), carmustine (BCNU), and nimustine (ACNU) have been utilized within the treatment of glioma, however, they have remained absent from considering the nearness of Foundational impromptu impacts counting camouflage of bone marrow and outrageous kidney/liver harm levels.Properly analyzed glioma patients have been seen to have impromptu impacts like demoralization or diminishing by the use of wafer-like chips of carmustine which easily gets disintegrate after use after the resection. (Chowdhary et al., 2015). It is for the most part anticipated that the clinical sensibility of nitrosourea-based treatment appears will be more unmistakable in glioma patients with destructive improvements appear whereas MGMT showcasespro methylation into the brain (Taal et al., 2015).

Whereas the advance to unused therapeutics related to gigantic expenses and moderate advance to Successful execution within the center, sedate repurposing has emerged as a charming technique, in light of Lower costs and an abbreviated time for advance to the working environment for another sign. For occurrence, an appraisal Testing Metformin, which is utilized within the affiliation for diabetes mellitus sort 2, appeared to have the advancement of free tirelessness to the patients with tumors,and diabetes which is treated with metformin was all-around extended in the world (Adeberg et al., 2015). Too, a joined evaluation of 1731 patients within the AVAglio, CENTRIC, and Center Preliminaries did not appear afundamental enhancement in all-around tirelessness with metformin, however, there was an epic danger degree saw for progression (Seliger et al., 2020). Nonsteroidal calming drugs like celecoxib have been inspected since drawing in Comes about in pre-clinical examination asoffice-based assessment (Sareddy et al., 2013). The plausibility of celecoxib as an adjuvant to Therapeutics, for illustration, TMZ, whereas appearing unfathomable bearableness, was scrappy to the degree giving a basic tirelessness advantage (Stockhammer et al., 2010).

At this point, the Coordinate organizes two or three multicenter startersto analyze the ampleness of disulfiram in a randomized Controlled assessment for gliomapatients. In common, a single reasonable, single-drug procedure has been put together for medicine openness, Lab-based appraisals, and clinical treatment. In any case, considering the innate heterogeneity of glioma headways, which is a multiple targeting process with the repurposing of a few drugs as a pharmacological Treatment appearsto have been thought of and is in advance. This was, to begin with, known as the CUSP9(Coordinated Undermining of Survival Paths) starter, be that as it may, has gone through a few movements andat this point known as CUSPv3 (Skaga et al., 2019). The genomic profiling of GBM ailments, gotten alongside the bioinformatics and organize of nuclear

inconsistencies with medicating libraries and the relating recognized arrangement obsessions, combined engineering a redo medicate blended drink which is being surveyed to treat gliomas (Byron et al., 2018). Assorted chemotherapeutic masters are being analyzed where the apportionments are being observed for a better view and listing the aggregate of the wrapped up and impelling starters. Here the information will be open through this location www.clinicaltrials.gov.

In 2011, a treatment advancement known as progression treating areas (TTFs), which employments center Repeat (200 KHz), low-power (1 V/cm) dependably passed on electric areas (Wenger et al., 2015) to unequivocally Target extending debilitating improvement cells by hindering mitosis was kept up to treat unpredictablegliomas By the FDA (Davies et al., 2013). The basic TTF contraption kept up by the FDA, known as NovoTTF-100A (Optune®), Delivered by Novocure, appears hindrance worked, with the field generator being mounted on their shaved scalp.Here outcomes of basic groundworks appear up to draw in; when TTF was gotten Beside TMZ chemotherapy, a fundamental progression in all things considered assurance (20.9 months versus 16 months) (Stupp et al., 2017) Differentiated with TMZ alone was seen, illustrating the foundation for additional consistent nuts and bolts studying The attainability of mixing TTFields with chemotherapy within the treatment of gliomas.

The present treatment process for glioma joins the mix of radiotherapy with Chemotherapy (Stupp et al., 2017). For the most part, whole intellect radiation treatment is utilized for the treatment. At any rate considering the side Impacts of openness of the standard cerebrum to radiation can show like scholarly inadequacy or current hone Employments in central radiotherapy treatment. Unique radiotherapy piece of 60 Gy is dependably passed on in abundance of 30 bits of 2 Gy with adjuvant TMZ (Stupp et al., 2017), with the fractionated treatment allowing ordinary Neural connections

including the headway treatment locale to recover between each treatment. Radioactive area Increasing speed endeavors have finished extended tissue growths and spontaneous impacts, with no colossal Alter in consistency (Raizer and Parsa, 2015), from presently into the predictable future there has been a work in examining other conceivable radiotherapy Based structures. Interstitial brachytherapy(it is a form of radiation therapy where a sealed radiation source is placed inside or next to the area requiring treatment) which needs the circumstance of radioactive isotopes (of course seeds) into the attentive area, despair is not a completely modern treatment, however, due to continuing with stresses For illustration, radiation spillage into the joining intellect, endeavors into making strides brachytherapy are In advance, counting the conceded transport of higher parcels of radiation, utilization of elective isotopes, Moreover, apportioned advancement through the blend of isotopes with monoclonal antibodies.

A treatment known As GammaTile, which joins embeddings exemplified radioactive cesium-131 seeds into the watchful Misery, was truly grasped by the FDA for the treatment of glioma and till this date depicted Credibility and victory (Gessler et al., 2020). Proton Pillar Treatment (PBT) in expansion has been inspected like a supportive elective for glioma, as the Related 'Bragg Top Effect' reduces radio dynamic responsiveness to the solidifying intellect with the utilization of More modest treatment target volumes, obliging a lower hazard of spontaneous impacts have been examined for illustration, neurocognitive Rot. Piece rousing appraisals have been performed, which showed some harm levels (Baba et al., 2021), however, it comparably has been shown that it may be an ensured treatment elective, fulfilling a slight consistency advantage for sporadic GBM (Scartoni et al., 2020). Arrange II preliminaries are in advance, considering the ampleness of PBT as a cutting-edge treatment veered from standard piece radiotherapy along withTMZ. The improvement of tall portion radiation to the perilous improvement can in like way be refined

through Gamma Cut Radiation surgery, which is so much useful for the treatment of shocking gliomas (Larson et al., 2014). It is watched that huge radiation-enacted edema happens to those who get much radio dynamic doses; notwithstanding, these confining accidental impacts were decreased, and understanding Continuance deferred when gotten in conjunction with bevacizumab (Koga et al., 2012).

1.2 Potential of drug repurposing in treating glioblastoma

An emerging space of intrigued in defilement treatment, strikingly glioma, is the repurposing of right medicines presently kept up for Diverse signs, considering questions of biochemical or metabolic Components which will familiarize glioma cell affectability with such arrangements. Evaluations aboutthe tirelessness relationship of these Solutions ought to be interpreted with caution and got to be seen as a Hypothesis passing on from a certain point of see. Typically, because it is difficult to control all the critical conditions which affect the relationship of these medicines, dosing was never normalized and not streamlined for appearing contradicting to progression Activity, and data grouping was commonly bound to achievement evaluations, in any case, not total dosing could be measured.

Epileptic patients suffer serious symptoms of GBM. Anti-epileptic medicines work on the progression of the tumor to connect the signal pathway throughout the damaged portion. For the foremost portion subordinate upon histone deacetylase inhibitory headway seen at tall obsessions in vitro and putative parcel provoking change, valproic ruinous has drawn unequivocally Intrigued. The viewpoint on longer diligence of patients treated with Valproic ruinous within the EORTC 26981 preparatory (Slomski, 2021) was not affirmed within the Examination of coming with respects to more critical clinical starter throughout masses (Happold et al., 2016), however, the

Mix of valproic harming with TMZchemo radiotherapy Keeps on being assessed (Krauze et al., 2015). Levetiracetam was proposed to Decrease the degree of MGMT in GBM (Bobustuc et al., 2010), in any case, no collaboration with the extraordinary results was found in a tremendous discretionary examination of Clinical starter data (Happold et al., 2016). At final, after principal intrigued in created by Glutamatergic hailing influencing neural transmission within the examination of GBM, the basic vitality on the AMPA receptor Talampanel, vanished when single-arm arrange II frequently create signals as promising, however, are not Prescient of achievement in randomized arrange III settings (Grossman et al., 2009).

Metformin, This savior of diabetic medicine is being advanced as an accomplice to glioma treatment by beliefs of anticipated modulatory impacts on assimilation, discernibly chopping down glucose responsiveness, the veil of insulin-Like advancement figure hailing, and unequivocally restriction of AMP-started protein kinase. Notwithstanding, current confirmation from pooled survey Examinations of clinical starter data doesn't keep up with the circumstances as the metformin needs to assist evaluation in GBM (Seliger et al., 2020).

1.3 Sorafenib: a ray of hope

Sorafenib, a small particle with diverse potential Targets, shows up especially elevating for treatment of Patients with dull cancers (Siegelin et al., 2010). Extreme enunciation not truly settled headway calculate receptor-A, a receptor Tyrosine kinase, have shown in each review about GBM, appearing one potential occupation at improvement advancement. Platelet-derived headway figure receptor may be an urgent target of sorafenib. One of the colossal Steps within the advancement of gliomas is angiogenesis. One of the key components is the vascular endothelial change figure, moreover an objective of the Multikinase inhibitor sorafenib. Encourage targets are Kinases RAF-

1 and B-RAF, the Fms like tyrosine kinase 3, and the c-KIT protein (c-KIT) (Wilhelm et al., 2004). Sorafenib has moreover been appeared to act as the Janus-impelled kinase/signal transducers and activators of record 3 hailings, recognized as basic for change capture and affirmation of apoptosis in GBM cells (F. Yang et al., 2010). In human GBM cell lines, crucial social orders, and mice xenografts, sorafenib discouraged cell improvement and began apoptosis into the tumors. The mix in with rottlerin, a protein kinase C inhibitor, was Delivered to see the potentiation of change square in human hazardous glioma cells (Jane et al., 2006). As of late, it has appeared that supplement K1 also updates the cytotoxic impact of sorafenib in tumor cells (Du et al., 2012). **Figure 3** shows the tumor treating fields of sorafenib on the apoptosis of tumor cells.



Figure 3: *Sorafenib and tumor-treating fields (TTFields) effects on the apoptosis in GBM cells (Clavreul et al., 2018; Sturm et al., 2012)*

1.4 Target pathways for glioblastoma

Neural hurt is recognized to be progressed or driven by harmed Qualities or by the odd endorsement of oncogene pathways (Vogelstein et al., 2013). Over 70% of DTC(Designer T Cells) patients have progressions with MAPK Pathway start in light of BRAF and RAS changes (Agrawal et al., 2014). Copy number developments within the PI3K/AKT pathway are superfluously critical for the turn of occasions and forcefulness (Xing, 2019). Notwithstanding the way that RAS is recognized to be a twofold activator of Both the MAPK and PI3K/AKT pathways, it astoundingly Starts the PI3K/AKT pathway in DTC (Agrawal et al., 2014) (Xing, 2019). One or two appraisals have appeared that sorafenib decreases the phosphorylation of mTORC1, both in vivo and in vitro (Hamed et al., 2015) (Zhang et al., 2015) (Zhai et al., 2014). In any case, the phosphorylation levels of AKT are by a comparable token Extended or lessened by sorafenib, which is something opposite to The finding presently depicted (Hamed et al., 2015) (Zhang et al., 2015) (Zhai et al., 2014) (L. P. Liu et al., 2012).

The likely instrument for this can be that responsiveness to sorafenib sanctions AKT Through the examination circle of mTOR (Zhai et al., 2014). Both MAPK and PI3K/AKT pathway practices upgrade the hurtful add up to of compromising turn of occasions and impact assertion from anticancer Treatment (Agrawal et al., 2014) (Xing, 2019). A clinical vital showed that a lower level of Nuclear pAKT clarification was related to the next speed of response to sorafenib (Yarchoan et al., 2016). The PI3K/AKT pathway is consistently distinguished by what happens from sorafenib treatment. In any case, the meaning of this structure and its significance in Clinical hone need to be in expansion inspected.

Sorafenibtosylate (Nexavar) was made as an RAF inhibitor however it in like way has progression against VEGFR-2, VEGFR-3, PDGFR, FLT-3, and Pack. Sorafenib is presently kept up to treat the state of the craftsmanship renal cell carcinoma (Escudier et al., 2007) and unresectable hepatocellular carcinoma (Llovet et al., 2008). Standard antagonistic events combine the runs, Weakness, nausea, hasty skin, and hand-foot condition. The review of such occasions is 38-45%. As the RAF-MEK-ERK course fills in as a Basic center in increment pathway and a small subset of GBM Shows B-RAF alteredas anticipated in constitutive MAPK (MEK-ERK) incitation, centering in on RAF adjacent angiogenic go-between VEGFR-2 and PDGFR could be bewildering in GBM (Basto et al., 2005). Moreover, sorafenib can control enunciation of activating record factor-5 (ATF5), a key determination calculated in tumor missing cells, and cover the change of human glioma xenografts in a murine demonstration (Sheng et al., 2010). A blend of sorafenib and metronomic TMZ (50 Mg/m2/day) persevered which was no longer related to colossal activity in drawn-out GBM (Reardon et al., 2011). An arrange II central of adjuvant sorafenib (400 mg twice bit by bit) notwithstanding TMZ taking after synchronous RT(Radio Therapy) along withTMZ In forty-seven patients with really inspected glioma disregard to appear Survival advantage with a center PFS of a half year and OS of 12 Months (Hainsworth et al., 2010).

In any case, 40% of patients did not get sorafenib amid the adjuvant arrange, for the foremost portion since of early issue progression, a few of which might have been "pseudoprogression" finished by Restorative impacts of RT with TMZ (Curran et al., 2007). Arrange I/II groundworks of sorafenib controlled in the meantime with RT/TMZ taken after by adjuvant TMZ in any case sorafenib in patients with really isolated gliomas are steady. Clinical groundworks of sorafenib as monotherapy or in Combination with chemotherapy or other minutely designated Operators, for case, tipifarnib (a farnesyltransferase inhibitor), erlotinib, Temsirolimus (Torisel®; CCI-779,

Pfizer, NY) (Wen et al., 2014), or bevacizumab in horrid GBM have been done or are in advance. Figure 4 shows the SREBP-1 and FAS apoptopic effect for inhibiting GBM cells bearing the EGFRvIII model and outlines the signaling process.



Figure 4:*SREBP-1 and FAS apoptopic effect for inhibiting of GBM cells bearing EGFRvIII model (Adeberg et al., 2015; Anandharaj et al., 2011; Hatori et al., 2006)*

1.5 AKT inhibition pathways

Akt, besides being called protein kinase B, may be a serine/Threonine-unequivocal protein kinase which goes probably as the center person which works in standard cycles like glucose maintenance, apoptosis, cell divide, and record. Three people Within the Akt family have been seen up until presently, expressly Akt1, Akt2, and Akt3. Whereas Akt2 is generally related to glucose transport and Akt3 is through and through offered in cerebrum tissue, Akt1 anticipates a

principal portion cell consistency and digestion (Garofalo et al., 2003) (Z. Z. Yang et al., 2004). The Akt course is endorsed by a tremendous social issue of occasions, most frequently through limiting of ligands, and made substances to distinctive receptors, here foremost Critical to handlereceptor tyrosine kinases (RTK). Limiting of ligands to RTK causes auto phosphorylation of tyrosine changes on the intracellular space of the receptor. This makes the selection of PI3K the Phosphotyrosine progressions through SH2 locale connectors within the Administrative space (p85) of PI3K. Which causes conformational changes within the reactant space of PI3K, which thusly fulfills the kinase task. This can be trailed by the PI3K mediating phosphorylation of layer-bound PIP2(Phosphatidylinositol-4,5-bisphosphate) to create PIP3. PIP3 at that point affiliations with the PH space of Akt, in this way, tying down it to the plasma layer and Permitting its phosphorylation and establishment by PDK1(Keeping an eye on and Cantley, 2007).

The development of Akt is forebodingly administered by PTEN Transport and CTMP (Pommery and Hénichart, 2005). The pieces of joining of the Akt pathway in tumor genesis are multifold. Akt has grounded against apoptotic workedout. These are gone on through Restraint of appearance of cytochrome c from the mitochondria or by its authoritative effect on diverse downstream effectors, for illustration NF-κB, Bcl-2 family proteins, FOXO record Variables, and MDM2, which thusly lock-in tissue advancement (Tune et al., 2005) (Y. Liu et al., 2004). In like way, Akt endorsement intervenes cell cycle headway through prevention of glycogen synthase kinase 3beta, Restricting the movement of p21WAF1 and p27Kip1 and by Phosphorylation of AKT/mTOR kinases (Liang and Slingerland, 2003). The final comes about in extended translation of cyclin D1, D3, and E Transcripts and passes on uncommon significance concerning Anti-unsafe progression therapeutics. mTOR obstruction by rapamycin Subsidiary, everolimus, has been appeared by, To turn AKT-subordinate prostate intraepithelial neoplasia (Majumder et al., 2004).

The Akt hailing pathway was other than impacts diverse pieces of Tumor genesis. For occasion, Akt invigorates angiogenesis working with unsafe advancement progress (Kar et al., 2005). This is often a quick eventual outcome of the intervention of the impacts of VEGF by the Flk1/VEGFR2-PI3K-AKT pathway (Shiojima and Walsh, 2002). Diverse signs of hurt like progression impedances and metastasis are in like way influenced by Akt starting (Lefranc et al., 2005). This can be a quick eventual outcome of the drawn-out entry of cross fragment metalloproteinase and the assurance of epithelial-mesenchymal Move (Thant et al., 2000). Akt has in expansion been shown to vivify telomerase headway and replication (W. J. Liu and Ding, 2001). **Figure 5** shows the PI3K–AKT–mTOR signaling pathways in GBM.



Figure 5:*PI3K–AKT–mTOR signaling pathways in GBM. S6K negatively affects the insulin–PI3K–AKT pathway as displayed (Puli et al., 2010)*

1.6 Incidence of glioblastoma around the globe

Agreeing to library information from 2011 to 2015, the conventional annually age-changed occasion of GBM within the Joined together States is 3.21 per 100,000 individuals (Reardon et al., 2011; Rokes et al., 2010). The speed of the event contrasts by age along with sex. The center age upon conclusion is sixty-five, with rates beating within the 75-84 age run (Garofalo et al., 2003; Sheng et al., 2010; Wen et al., 2014). People are 1.58 occasions more conceivable than females to develop glioblastoma, with an annually age-changed repeat of 4.00 per 100,000 individuals separated from 2.53 per 100,000 individuals. To the extent of race or ethnicity, non-Hispanic whites have the most excellent predominance, taken after by American Indians or Gold country Locals, who have a 40% lower rate (Hamed et al., 2015; L. P. Liu et al., 2012; Xing, 2019). GBM is by and expansive conventional in North America, Australia, and Northern and Western Europe all through the planet (Baba et al., 2021; Raizer and Parsa, 2015). Within the Joined together States, the thegeneral rehash of GBM is 9.23 per 100,000 individuals. Within the Joined together States, the annually repeat of glioma is 4,444 2-3 cases for every 100,000 individuals, which addresses by and large 28% of 4,444 of all principal mind advancements (Cohen et al., 2013; Sepúlveda-Sánchez et al., 2017; Stupp et al., 2017). It may be a marvelous however astoundingly dangerous contamination. Various long periods of examination seen etiological components (family parentage, phenomenal acquired undermining improvement shortcoming issue, ionizing radiation, and 10 free complaints of hereditary hazard), to some degree considering the way that glioma could be a sort of contamination, especially going after for inquiring about (Cemeus et al., 2008; Cohen et al., 2013; Sepúlveda-Sánchez et al., 2017; Stupp et al., 2017; Wei et al., 2008; Zustovich et al., 2013).

1.7 Risk factors of glioblastoma

Among the specific risk components, momentous thought ought to be paid to the affiliation between affirmation from hypersensitivities and unsecured components and the probability of glioma (Majumder et al., 2004; Pommery and Hénichart, 2005; Thant et al., 2000).There is a solid affirmation for an odd chitchat affiliation among gliomas and inauspiciously defenseless infection. The proof depends upon data coming about to looking for 8 observational examinations (with a sum of 3450 glioma patients) (Du et al., 2012; Wilhelm et al., 2004; Xing, 2019). The hazard of glioma is at that point what is once more related to asthma, skin bothering, and hypersensitivities. No such event has been found in inquiring about on assessment.

The researchers assessed the conceivable impact of the overactive secure framework that goes with the adversely frail affliction on the covering of astounding glioma cells. The outcome of the assessment did not move subject to topography, consider arrange, and 4,444 specific excessively delicate conditions (Byron et al., 2018; Sareddy et al., 2013; Skaga et al., 2019). They reflect the cautious impact of extraordinary sensitivity on the change of gliomas. The producers underlined that methodological confinements are most likely not attending to clarify the saw influence which assistsin approaching appraisals which are required. There are cases of the familial events of gliomas and a natural propensity to procured gliomas has been found in 5 to 10% of cases (S. Y. Lee, 2016; Seliger et al., 2020; Stupp et al., 2005). At long last, a few momentous intrinsic sicknesses, for the occasion, neurofibromatosis sorts 1 and 2 and Bourneville tuberous sclerosis are besides related with an enlargement within the repeat of unsafe improvements counting gliomas. No such event has been found in inquiring about meningiomas.The outcome did not move subject to any therapy (Byron et al., 2018; Sareddy et al., 2013; Skaga et al., 2019). They reflect the cautious impact of extraordinary sensitivity on the advancement of gliomas. There are cases of

the familial events of gliomas and an intrinsic inclination to obtained gliomas has been found in 5 to 10% of cases (S. Y. Lee, 2016; Seliger et al., 2020; Stupp et al., 2005). A curious issue, but inconsistently alluded to within the composition, is the nearness of components that decrease the hazard of glioma, compared to begin of asthma (Byron et al., 2018; Chowdhary et al., 2015; Stockhammer et al., 2010). There are some the attested chance components for GBM. Openness to ionizing radiation is the essential recognized risk figure for glioma and the singular modifiable hazard figure. An inverse relationship among gliomas and a past stacked up with sensitivities, hypersensitivities, and other immune conditions have similarly been seen, ignoring the way that is the specific standard considering for this has not however been clarified (Yarchoan et al., 2016; Zhai et al., 2014; Zhang et al., 2015). There are marvelous hereditary conditions related togliomas, such as the LiFraumeni issue and Lynch issue; in any case, these areas and 1% of cases. There's no conclusive confirmation between cell utilization and the enhancement of glioma, however more evaluations, and affiliations are required (Di Nunno et al., 2021; Grech et al., 2020; W. J. Liu and Ding, 2001).

Chapter 2:

Methodology

The resources were based on the available literature on the topic: “Sorafenib for the Treatment of Glioblastoma Multiforme”. The recent articles were searched from the databases like Pub Med, Science Direct, Google Scholar, SCOPUS using keywords such as, “Glioblastoma”, “Sorafenib”, “AKT inhibition” etc. The idea was to collect the background information first on the topic to see the recent trends in this field. Then, the research gap was determined by going through the collected articles. There were inclusion and exclusion criteria to filter out the articles and select those which is to be used in the writing process. Specific headings and subheadings were constructed to form the basic framework of the project. Under each of the headings and subheadings, research questions were formed. The answers to the research questions were collected by going through the articles from different sources mentioned above. The in-text citations and the bibliography were generated using the Mendeley Desktop version reference managing software. **Figure 6** shows the outline and the methodology of the article retrieval and selection process, and **Figure 7** shows the purpose of writing a literature review.



Figure 6: *Methodology of the literature review*

Chapter 3:

Standard Treatment Procedures for Glioblastoma



Figure 7: *GBM therapy timeline (Xie et al., 2021; R. Yang et al., 2021)*

3.1 Radiotherapy

Radiotherapy has for a few times been utilized within the treatment of glioma to work on both neighborhood control and continuance, and it remains a critical technique.**Figure 8** shows the timeline of the glioblastoma multiforme therapy. At the show, standard Radiotherapy after therapeutic method passes on 60 Gy in 2-Gy parts more than approximately a month and a half in the mix with TMZ.Other Parcel plans have been inquired about this but those did not have any clear Advantage. Particularly, there's no sign for fractionated Parcels >60 Gy (Lawrence et al., 2010) The threat of radiation decay with concurrent chemotherapy, unexpected volume of the

cerebrum Lit, and the parcel to essential developments are noteworthy Thoughts. For occurrence, with brainstem commitment or amazingly colossal cancer volume, an imperceptibly lower parcel of 54 to 55.8 Gy in 1.8-Gy parcels or 57 Gy in 1.9-Gy parts may well be utilized. Cancer amount is characterized by subordinate on preoperative, Moreoverpostoperative MRI imaging along moved forward T1 and Fluid contracted inversion recovery (FLAIR)/T2 groupings to initially decide the net cancer amount.

Here are a few assortments within clinical development volume edges and to the utilization of 2 stages (fundamental along with lift volumes) or 1 Organize (single volume) for target volume definition, agreeing on neighborhood regulation practice is necessary. (Cabrera et al., 2016) other associates or promising Methodologies to communicate radiation have been tested. Up until this point, none have shown way better ampleness over standard fractionated radiotherapy. Ancient patients developed ≥70 a long time are known to have a more deplorable figure and along these lines address a noteworthy sub gathering. Radiotherapy had an illustrated impactful advantage and solid Care alone. (Keime-Guibert et al., 2007) Be that as it may, the advantage was modest, moreover, long course radiation assessment on more random patients may not be suitable. Hence, thinks about have tried out other elective strategies for such patients. Hypofractionated radiotherapy, with a normally comparable parcel of 40 Gy passed on in 2.67-Gy divisions over 3 weeks, has been shown to bring almost comparative perseverance outcomes. Besides, hypofractionated in Blend with concurrent and adjuvant TMZ Has since appeared encouraging. (Perry et al., 2017)Without a doubt More constrained fractionation plans, like 34 Gy in 3.4-Gy Divisions or 25 Gy in 5-Gy parcels, can moreover be thought of, especially in incredibly delicate patients. (Malmström et al., 2012) In ancient Patients along with MGMT sponsor methylation, TMZ Alone without radiation is another choice and is talked approximately Underneath. An

unequivocal assessment of Capacity in the mix with sub-atomic boundaries is vital some timeand more effective than recently used medication. (A. Wick et al., 2017) at rehash, reirradiation could be a reasonable choice in Chosen conditions. Customarily, this would be held for more energetic patients with awesome execution status. (Cabrera et al., 2016)

Comparative to Therapeutic strategies, there are no randomized preliminaries appearing survival advantage. After the consideration of All things there comes a new strategy which is stereotactic radiosurgery (SRS) along with short-course hypofractionated stereotactic radiotherapy, as most rehashes happen interior as of late lit Brain. (Cabrera et al., 2016) The security of SRS in this setting has been a fiendish presence in a arrange 1 ponder. (Shaw et al., 2000) Hypofractionated stereotacspasm radiotherapy might display a lower danger for radionecrosis, in showing disdain toward the truth that there is no quick examination with SRS. (Fogh et al., 2010) There's No standard as to parcel fractionation schedule, target volume, or stereotactic system. Uniting reirradiation with essential treatment, particularly bevacizumab, has in addition been examined probably and conceivably may moreover reduce Paces of radionecrosis. (Gutin et al., 2009) (Cabrera et al., 2016).

3.2 Chemotherapy

Cytotoxic treatment in the sake of gliomas has created, vast since of the underwriting of TMZ - an alkylating master for as of late analyzed GBM. Energetic Pros consolidate furthermore the nitrosoureas: carmustine (BCNU) and lomustine (CCNU), platinum pros, etoposide, irinotecan, and PCV blend.TMZ could be a fresher verbal alkylating pro that features an Incredible entrance

into the central tangible framework. It is a midazotetrazine subordinate of dacarbazine. It has 96-100% bioavailability Too, progresses the methylation of the O6 position on guanine. It was supported in 1999 for utilization against perilous Gliomas. Critical harm levels consolidate ailment and myelosuppression (routinely Moo platelet tallies). Regularly, a verbal 5-HT3 terrible fellow is given 30–60 Minutes some time recently each parcel. Estimation is by and large started at 75 mg/m2 each day At the same time with around a month and a half of common radiotherapy to the cautious pit, What's more, trailed by 6 adjuvant cycles with upkeep parcel at 150 mg/m2 Day by day p.o. for 5 days for the central cycle and on the off chance that exceptionally much persevered, expanded To 200 mg m−2 day−1 for 5 days in 28-day cycles (Chinot et al., 2001; Villano et al., 2009).

3.3 Immune Therapy

If we see the accomplishment which appeared through immunotherapeutic frameworks to treat diverse illnesses, So broad effort to moreover making an elucidation of this to make this strategy useful to treat GBM Patients. Generally, the cerebrum is seen as a secure favored organ because of the nearness to Blood cerebrum obstacle (BBB) and the shortage of a lymphatic squander system. Regardless, antagonistic to cancer immune Responses have been seen in intellect developments (D'Alessio et al., 2019), which are thought to work with the presence of lymphatic framework (Song et al., 2020). As a rule, immunotherapy has shown large fruitful results to treat growths with large mutational weight (Riviere et al., 2020), yet glioma has a low cancer mutational weight, while likewise showing an immunosuppressive climate (E. K. Liu et al., 2020), and the

additional entanglement that chemotherapeutics can additionally advance an immunosuppressive impact (Sengupta et al., 2012).

In any case, as immunotherapy incorporates saddling the safe system to devastate development cells, a couple of unmistakable systems have been explored to assist have insusceptibility against GBM. Safe assigned spot bar is utilized to achieve affectation to secure system With a basic effort focusing in ruining restricting of assigned spot receptors within insusceptible cells Like Cytotoxic T-Lymphocyte Antigen 4 and Modified Cell Downfall protein 1 (PD-1) (late T-cell limitation) to their relating ligands on cancer cells, progressing more practical T cell response against the development of tumors (Maxwell et al., 2017). Different assigned spot inhibitors that have been bolstered for utilizing in several illnesses have been tried within the treatment of monotonous GBM, such as nivolumab, pembrolizumab, durvalumab, atezolizumab (Romani et al., 2018). The preliminary results have been not precisely energizing; in any case, there are advanced examinations concerning mulling over biomarkers that will Recognize what kind of patients might react to assigned spot blockade, the mutational pile of development as An marker of response, organization of PD-1 antibodies going before cancer resection to actuated an early Unfriendly cancer response, or explore the impacts of radiotherapy, which may be a synergistic facilitator of Response to immunotherapy (Rajani et al., 2019) (Cloughesy et al., 2019).

Safe framework of microorganism treatment incorporates the utilization of autologous T-cells, have been hereditarily outlined to communicate Whimsical antigen receptor (CAR) and which is FDA-supported to treat Hematologic malignancies. Many arrange I preliminaries have given engaging symptoms as distant as prosperity, Credibility and conceivable ampleness against pertinent glioma surface antigens counting IL13Ra2, HER2, EphA2 and EGFRVIII (Bagley et al., 2018). In spite of the reality that the basic outcomes are promising, it is anticipated that, Since

genuine level of heterogeneity shown by glioma developments, T-cell treatment will be controlled like blend treatment, conceivably with safe assigned spot blockade. Counter acting agent based processes are furthermore being inspected as a likely strong immunotherapy for GBM by quickening an antigen-explicit effector T cell response against cancer unequivocal antigens (TSA) or Development related antigens (TAA). A number of strategies are brought up like counting cell-based tradition and non-cell based tradition. Planned peptide progressions that deliver an assigned Insusceptibility against cancer related antigens bound to noteworthy histocompatibility buildings structure to peptide antibodies. An outline of two peptide antibodies where one of them is rindopepimut (EGFRvIII) (Swartz et al., 2014) Also, SurVaxM (Survivin) (Fenstermaker& Ciesielski, 2014). While rindopepimut showed amazing reactions in the beginning stage Studies (Swartz et al., 2014), an endurance advantage was not seen in the stage III assessment (Weller et al., 2017). Be that as it may, a different Stage II investigation consolidating rindopepimut with TMZ further developed movement free and in general Endurance for GBM patients (J. Schuster et al., 2015), just as the exhibit of empowering brings about a stage II investigation Consolidating rindopepimut with bevacizumab in the treatment of repetitive GBM patients (Reardon et al., 2020).

A stage two Study assessing SurVaxM has shown enhancements in movement free by and large endurance (Fenstermaker et al., 2016). Warmth shock proteins have additionally been used to convey an assortment of growth antigens and are intended to make an enemy of cancer fiery reaction. HSPPC-96 is one such antibody, that is gone through stage II, multicenter clinical preliminary for intermittent glioma (Bloch et al., 2014). Autologous cell developmentBased immunizations utilize cytotoxic T lymphocytes which are actuated with patient-inferred cancer cells, in this way get an insusceptible response, at whatever point they are oncemore getpresented into the Persistent (Chamberlain, 2014). Dendritic cell immunizations depend on tolerant induced

dendritic cells that are revealed to cleansed cancer express antigens or development cell isolates got from cancer earlier to being presented to the quiet, along these lines starting CD8+ and CD4+ T cells. An organize I preparatory with An autologous dendritic cell immunization has appeared a relationship between the enunciation level Of growth-related antigens on the glioma cells and postponed for the most part speaking/movement free tolerant Continuance (Phuphanich et al., 2013). Viral-based treatment that incorporates the movement of the quality of intrigued by implies of viral vectors is also being examined as a sort of immunotherapeutic agent to treat glioma. Oncolytic contaminations can particularly copy in development cells, rousing cytotoxic impacts, in the long run giving an immunostimulatory Effect. DNX-2401 could be a replication-skilled adenovirus that utilizes development express integrins to make Oncolytic impacts (F. F. Lang et al., 2018), while PVSRIPO (lessened polio-rhinovirus delusion) perceives CD155 (poliovirus receptor), which is generally communicated in growth cells (Walton et al., 2018).

3.4 Medication repurposing

An emerging space of intrigued in threatening development treatment, conspicuously GBM, is the repurposing of medicines that are presently upheld for diverse signs, in see of doubts of biochemical or metabolic Arrangements that will show glioma cell affectability to such drugs (Beug et al., 2018; Kang et al., 2017). Essentially, audit examinations of the continuance relationship of each one of these Solutions ought to be deciphered with alarm and got to be thought of Hypothesis making because it was (Beug et al., 2017; J. L. Huang et al., 2017; Rasmussen et al., 2018). Typically because it is difficult to control for Comorbidities that provoked the organization of these medicines, dosing was never normalized and not streamlined for showing

against cancer Activity, and data grouping was commonly confined to breakthrough examinations, in any case, not total dosing (Benitez et al., 2017; Beug et al., 2017; Rasmussen et al., 2018; R. Yang et al., 2021).

3.4.1 Anti-Epileptic Drugs

Against epileptic solutions in show disdain toward of numerous a long time of investigation, no persuading verification to assist a Continuance progressing activity of against epileptic solutions in cerebrum development has been obtained. Fundamentally, subordinate to histone deacetylase inhibitory development seen at tall centers in vitro and putative differentiation-instigating activity, valproic acid's destructive nature has drawn particularly Intrigued. The recognition of longer perseverance of patients treated with Valproic destructive within the EORTC 26981 preparatory (Maxwell et al., 2017) was not asserted in an Examination of coming about greater clinical preparatory populaces (Happold et al., 2016), however, the Mix of valproic destructive with TMZ chemo radiotherapy Keeps on being examined (Krauze et al., 2015). Levetiracetam has been proposed to Reduce the degree of MGMT in glioma (Bobustuc et al., 2010), in any case, no alliance With positive result was found in a colossal discretionary examination of Clinical preparatory data (Happold et al., 2016) At long final, after basic intrigued within the work of Glutamatergic flagging affecting neurotransmission within the science of GBM, the fundamental vitality on the AMPA receptor terrible fellow, Talampanel, kicked the bucket down when unmistakably single arm organize II Thinks about routinely deliver signals deciphered as promising, however are not Prescient of accomplishment in randomized arrange III settings (Grossman et al., 2009).

3.4.2 Metformin

This foe of diabetic medicine has been advanced as an right hand to GBM treatment in light of accepted modulatory results for digestion system, prominently bringing down glucose openness, concealment of insulin-like advancement calculate hailing, and unequivocally prevention of AMP-activated protein kinase. In any case, current confirmation from pooled survey Examinations of clinical preparatory data doesn't maintain the see that metformin Warrants encourage examination in glioma (Seliger et al., 2020).

Chapter 4:

Neural Pathways



Figure 8: *Invasion pathways to GBM guidelines (Ahmadov et al., 2021; H. Li et al., 2021)*

4.1 The PI3K/AKT/mTOR pathway

The PI3K/AKT/mTOR pathway is sanctioned by transmembrane Tyrosine kinase improvement figure receptors, transmembrane integrins Moreover like G-protein-coupled receptors. Upon sanctioning this kind of receptors, down to earth PI3K moves to Plasma layer where prompts the creation of phosphatidyl- Linositol 3,4,5-triphosphate (PIP3) from phosphatidylinositol Bisphosphate (PIP2).PIP3 sanctions serine/threonine kinase Phosphoinositide-subordinate kinase 1 (PDK1) and AKT (at Threonine 308). Phosphatase and tensin homolog (PTEN) tries there to adjust PI3K motioning by dephosphorylating PIP3 to PIP2. (Carracedo&Pandolfi, 2008)Ordered Akt phosphorylates the FOXO subfamily, that prevents record of some favorable to apoptotic proteins, which moreover can Limit apoptosis by phosphorylating and inactivating strong of Apoptotic proteins like, GSK3. (X. Fang et al., 2000) Additional capabilities Incorporate the phosphorylation and debasement to the blocker of B (IB), that comes up with large amount of atomic factor kappa B (NF-) activity and transcriptional induction of endurance-enhancing genes., (Bai et al., 2009) it additionally balances MDM2, which restrains P53 (an activator Of cell-cycle arrest). (Burris, 2013)

Akt straightly and implicitly stimulates the activation of mTOR, which is found in two distinct structures: mTORC1 and mTORC2. The proteins mTOR, Raptor, mLST8, and PRAS40 make up mTORC1. S6K1 and hence S6 are activated by mTORC1, resulting in cell growth and development. It also causes eIF4E restricting protein 1 (4E-BP1) to be restrained, allowing the formation of eukaryotic inception factor 4F (eIF4F) and protein translation. (Memmott & Dennis, 2009) mTORC2 is made out of mTOR, Rictor, Sin1 and mLST8 and its job is less understood. (Memmott & Dennis, 2009) It has been discovered that mTORC2 initiates PKC, advancing its kinase activity. (X. Li & Gao, 2014) It is too felt that mTORC2 might participate in cell endurance

and cytoskeletal organization. (G. Yang et al., 2015) Hypoxia-inducible factor 1 (HIF1) has been shown to be directed by mTOR, resulting in downstream activation of vascular endothelial development factor (VEGF) and increased angiogenesis. (Land & Tee, 2007). **Figure 9** shows the invasion pathways of glioblastoma multiforme

4.2 The Ras/MAP/ERK pathway

The Ras/MAP/ERK signaling pathway which act for various cell factors involved with angiogenesis, cell proliferation, motility, and endurance is managed by this flagging route, which gets activated through cell surface receptors. Activation of Ras protein occurs when GDP is exchanged for GTP, resulting in the activation of MAP kinases, which then phosphorylate downstream ERK.. (WINTER et al., 1960) Transformations in cytokine receptors, including as Flt-3, Kit, and Fms, or overexpression of wild-type or transformed receptors, commonly activate this pathway in particular malignancies. (Steelman et al., 2010) Actuation of HIF-1, which promotes carcinogenesis, is also triggered by activation of the Ras/MAP/ERK pathway. (Lim et al., 2004) In the pathophysiology of GBM, RTK signaling pathways play a vital role. RTK has seen a massive number of modifications and cancellations. Various cancers, including GBM, have distinct signaling pathways. In 86–90 percent of GBM patients examined, the RTK/Ras/PI(3)K pathway was shown to be altered. Ras actuation in combination with AKT pathways have been shown to promote the development of glioma cancer in mice. (Holland et al., 2000)

In the progression of grade III anaplastic astrocytoma to grade IV GBM, the AKT flagging pathway is critical. Malignancies that communicate with AKT tend to develop at a faster rate than cancers that do not communicate with AKT. (Sonoda et al., 2001) Furthermore, it has been

demonstrated that blocking the PI3K/AKT pathway inhibits the expression of GBM cells, (Gallia et al., 2009) bringing up the value of this route in the pathophysiology of GBM, blockers of PI3K/AKT/mTOR flagging pathway are over-represented. PTEN, for example, is altered or deleted in 36–44 percent of GBM instances. (S. I. Wang et al., 1997) PTEN deficiency is also connected to invulnerability avoidance in GBM malignancies, with PTEN mutations are also connected to high the expression of the invulnerable suppressor designated spot PD-L1. (Parsa et al., 2007) Another analogy seems to be the cancer suppressor Neurofibromin 1 (NF1), which prevents Ras from working. (Dasgupta & Gutmann, 2003) NF1 has a region that is very similar to the reactant space of Ras GTPase-initiating protein (p120GAP), and as a result, it energizes Ras GTPase, causing Ras bound GTP hydrolysis into GDP and Ras activity inactivation. (Yunoue et al., 2003) The link between Neurofibromatosis type-1 (an infection represented by NF-1 Change) and GBM incidence suggests that NF-1 is involved in the progression of glioma. (Hatori et al., 2006).

4.3 PI3K/AKT Pathway

After reviewing the frequency and mortality of brain along with Focal sensory system malignancies are respectively 1.6 percent and 2.5 percent, particularly throughout the world, GBM, the most well-known essential harmful cancer, adds to the helpless guess mostly because of its resistance to radiation treatment. Hyper-enactment of the PI3K/AKT pathway at glioma is the reason behind the mutations of PIK3CA or PIK3R1 (18.3%) and other PI3K family qualities (6.8%) has prompted investigators to look for new designated treatment process to overcome the illness. (Lope et al., 2010). Furthermore, knocking down PIK3CA or PIK3R1 reduces cell

suitability, relocation, and incursion in GBM cells by hypo initiating AKT and FAK. Furthermore, overexpression of p110 is seen in a development of glioma cell lines far more frequently than in human cancer testing. In vitro and in vivo, PIK3CB knockdown repress cell multiplication and induces caspase-subordinate death in glioma cells, rather than suffocating cell migration. (Zhao et al., 2016). In this vein, PI3K blockers are widely examined in gliomas for a long time, and a few have shown promising results in the treatment of the disease. Even though about 50 PI3K blockers have been developed which were supplied to treat cancer, there a small number of drugs, such as BKM120, XL147, XL765, and GDC-0084, these drugs have practically entered clinical trials for glioma treatment. (Lope et al., 2010). In vitro, inhibitors of certain p110 isoforms, such as A66 or PIK-75, might successfully limit glioma cell expression, endurance, and motility. (Jamieson et al., 2011), while blocking of p110β by TGX-221 which just captures cell movement, and create hindrance of p110δ by IC87114 or CAL-101 tolerably inhibits cell multiplication and relocation in the gliomas (Höland et al., 2014).

However, PI3K blockers like as A66 and BEZ235 have been reported to rise up the evolution of malignant growth foundational microorganism (CSC) characteristics in GBMwhere CSC models show therapy resistance. (Jones et al., 2016). Interestingly, despite the fact that various AKT isoforms are thought to act distinct roles in GBM, adding AKT3 delays tumor progression. (Joy et al., 2016), truly, the AKT blockers perifosine is okay yet do not show effects as monotherapy for GBM (Kaley et al., 2019). AKT inhibitors are still a bit of a thorn in the side when it comes to treating GBM. PTEN was profoundly engaged with the neurotic effects of the PI3K/AKT pathway in glioma, based on the fact that 22 percent hereditary changes of PTEN were identified in GBM, particularly profound cancellation, which is the reason behind deficiency of capacity of PTEN growth silencer, and PTEN was profoundly engaged with the neurotic activities of the PI3K/AKT

pathway in glioma. (Álvarez-Garcia et al., 2019). In the meantime, hereditary deficiency of PTEN is related with each subtype of GBM (Verhaak et al., 2010). Furthermore, in GBM, the glucose-regulated protein 78 (GRP78) interacts with 2-macroglobulin to activate AKT1 via PDK1 and mTOR to improve malignant growth cell multiplication along with radio-treatment resistance. (Dadey et al., 2017).

The immune response that is hostile to GRP 78 can reestablish malignant cell growth susceptibility to radioactive therapy, which fails cell multiplication also improves apoptosis along with shows benefits of focusing on malignancy cells without damaging healthy cells. In addition, a combination of anti-GRP 78 neutralizer and radiation therapy (XRT) has a stronger growth inhibitory impact. In contrast to GBM, the genetic alteration of PIK3CA (2%) and PIK3R1 (0.3%) in medulloblastoma, which is the most hazardous cerebrum growth that primarily affects children and has a survival rate of up to 70% following dynamic therapy, is less frequently detected. (Gottardo&Gajjar, 2006). However, because FBW7 corrupts SOX9 under the guidance of GSK3, improving phosphorylation of AKT via PI3K or mTOR to restrict GSK3 in MBM, which leads to SOX9 debasement, is reduced. FBW7 deficiency increases SOX9 protein levels, increasing the danger of malignant development and providing protection against cisplatin. (SuryoRahmanto et al., 2016). As a significant oncoprotein inhibitor, when FBW7 is erased or transformed, it can make growths happen straightforwardly (Y. M. Tan et al., 2008). In MBM, so-called PI3K pathway restriction offers tremendous therapeutic promise. Furthermore, investigations suggest that a combination of PI3K inhibitors, mTOR inhibitors, and cisplatin has a more beneficial impact. (SuryoRahmanto et al., 2016), and how well LY3023414 works in repetitive MBM is being tried in a progressing clinical preliminary (NCT03213678, Table 2).

Chapter 5:

The potential of sorafenib as a potent glioblastoma treatment

5.1 Sorafenib's Mechanism of Action

Sorafenib is a seronine/threonine and RTK inhibitor that targets VEGF receptor 2, FMS-like tyrosine kinase 3 (FLT3), platelet-inferred development factor (PDGF) receptor, and fibroimpact development factor receptor-1, among others (FGFR1) (Hainsworth et al., 2010; Iwanami et al., 2013; Sabanci et al., 2014). It was originally developed as a compound enhanced blockers of the Raf kinases A-Raf, B-Raf, and C-Raf (Raf1) by Bayer Pharmaceuticals and Onyx Drug (Carra et al., 2013; Davies et al., 2013; Stupp et al., 2017; Taal et al., 2015). Raf kinases are the fundamental kinases in the Ras/Raf/MEK pathway/mitogen-activated protein kinase (MAPK) pathway, and they are often liberated in human cancers, altering cell growth and endurance. Sorafenib blocks the wild-type cells of the tumors. (Carlomagno et al. 2006; Gollob et al. 2006; Wilhelm et al. 2004) (Figs. 1 and 3). Sorafenib doesn't repress MEK1, ERK1, epithelial development factor receptor 1 (EGFR1/HER1/ErbB-1), HER2/ Neu (ErbB-2), or insulin-like development factor receptor 1 (IGFR1) (Wilhelm et al. 2006, 2004). Sorafenib, demonstrated anticancer activity whether it is acting solely or combined with other drugs in colon, breast, and non-small cell cellular breakdown in the lungs (NSCLC), melanoma, thyroid cancer, hepatocellular cancer (HCC), RCC, lymphoma, and Flt-3 freak leukemia in xenograft cancer models. Figure 10 shows the Sorafenib and metformin's molecular targets in GBM



Figure 9:*Sorafenib and metformins molecular targets in GBM (J. Wu et al., 2021; W.-B. Yang et al., 2021)*

5.2 Cell Proliferation Inhibition by Sorafenib

Clinical trials have revealed that sorafenib, which is amultikinase blocker, may provide a significant advancement to treat HCC(hepatocellular carcinoma), particularly unrespectable HCC. (Bruix& Sherman, 2011). Sorafenib, The FDA has approved it, and it has exhibited to be successful against a few strong gliomas. It is now a routine treatment for HCC. (L. Lang, 2008). Sorafenib inhibits PDGF, VEGF, FLT3, c-Kit, and Raf signaling, according to previous research. (Hahn& Stadler, n.d.). Sorafenib has great impacts on cancer cells as well as in the encompassing endothelial cells (Ranieri et al., 2012). The fundamental system is accepted to include serious inhibition of ATP restricting to the synergist spaces of the different kinases (Wilhelm et al., 2002). Sorafenib has been demonstrated in preclinical studies to have strong anti-proliferative effects and to reduce growth attack. Acceptance of apoptosis is also thought to interfere with sorafenib's anti-cancer effects in HCC cells.

An early study found that inhibiting eukaryotic interpretation inception factor 4E (eIF4E) phosphorylation and down-regulating the anti-apoptotic protein myeloid cell leukemia 1 (Mcl-1) contribute to sorafenib-induced apoptosis. (Yu et al., 2005). Nonetheless, since inducing apoptosis in robust development cells by deleting Mcl-1 alone is frequently insufficient, the anti-cancer mechanism that underpins sorafenib's action has yet to be fully described. Forkhead box M1 (FoxM1), a member of the Forkhead box (Fox) family of record factors, has been implicated in the etiology and progression of a variety of human cancers, including HCC. (Ho et al., 2012). Concealment of FoxM1 articulation can prompt mitotic shaft surrenders, chromosome disaggregation, mitotic disaster, and cell cycle arrest (I.-C. Wang et al., 2005). FoxM1 is a vital controller in the G1/S and G2/M changes, what's more, M stage movement. FoxM1 plays part in cross-talk with numerous oncogenic flagging pathways (Z. Wang et al., 2009)and controls the

articulation of a few cell cycle controllers, including p21Cip1, p27Kip1, cyclin B, aurora B kinase, survivin, and PLK1 (Laoukili et al., 2007). Likewise, the phosphorylation of FoxM1 using the Raf/MEK/MAPK pathway invigorates FoxM1 atomic movement and along these lines its transcriptional action during G2/M (Ma et al., 2005).

FoxM1 has been shown as a reliable target for capturing malignancy development and migration. The depletion of FoxM1 in cancer-causing mice models can dramatically reduce disease cell proliferation and cancer formation in a variety of strong growths. When mice with the FoxM1 transgene were subjected to growth recruitment through carcinogens, a controlled increase in the favorable to liberation, quantity, and size of growths was seen. (Balli et al., 2011). FoxM1 can advance growth angiogenesis by initiating VEGF articulation through direct restricting to Forkhead restricting components (FHRE) of the VEGF promoter (Y. Zhang et al., 2008). Down-guideline of FoxM1 has been displayed to repress intrusion furthermore, angiogenesis by diminishing MMP-2 and MMP-9 expression (Z. Wang et al., 2007). Past examinations have announced that senescence was seen in early-stage fibroblasts got from FoxM1 thump out mice and that expanded degrees of FoxM1 checked H2O2-incited senescence (Y. Tan et al., 2007). Ongoing examinations have uncovered that FoxM1 partakes in deciding enemy of malignancy drug affectability furthermore, may advance the improvement of procured drug resistance if abnormally initiated or expressed (Myatt & Lam, 2007). We got results like sorafenib HCC cells in vitro also, in vivo by stifling FoxM1 through the up-guideline of p53. Our outcomes shed light on the counter disease component of sorafenib and give a structure inside which FoxM1 can be controlled to work on the adequacy of designated treatment.

5.3 AKT Pathway Inhibition by Sorafenib

Cell survival enhancement is the best examined feature of the Akt pathway. Akt builds up its anti-apoptotic activity by phosphorylating downstream substrates which lead to the apoptotic machinery. (Perry et al., 2017; Rajani et al., 2019). Akt indirectly suppresses the pro-apoptotic protein p53's function by increasing Mdm2, which raises p53 degradation. For acting on genetic damage, p53 stimulates the synthesis of pro-apoptotic proteins, ensuring that faulty genetic information is not passed on to descendant cells. (Bagley et al., 2018; Song et al., 2020).

Through activation of the PI3K-Akt pathway, tumor cells gain the ability to survive after not being able to repair DNA damage (Bloch et al., 2014; D'Alessio et al., 2019). Furthermore, Akt signaling causes the anti-apoptotic target genes NF-B (nuclear factor B) to be transcribed. IKK (IB kinase) is activated by Akt, which causes IB (the NF-B inhibitor) to be degraded (Malmström et al., 2012; Swartz et al., 2014). The NF-B that has been unmasked may now reach the nucleus and stimulatethe production of pro-survival target genes (Reardon et al., 2020; Riviere et al., 2020). BCL-anti-apoptotic XL's activity is also restored by 3, 5 base pairs where Akt inactivating its inhibitor, BAD. 3, 5 the transcription of their death target genes is inhibited when the Forkhead family of transcription factors is inactivated by Akt. Phosphorylation of p21/WAF by Akt improves the stability of p21. P21 protein levels are elevated in a variety of aggressive cancers associated withchemoresistance. Active Akt-positive glioma cell lines had greater p21 stability and were more resistant to paclitaxel. Proliferation and activation of the protein kinase Akt By modulating proteins in the cell-cycle machinery, Akt signaling can also impact proliferation

(Cabrera et al., 2016; Gutin et al., 2009; Lope et al., 2010). By inactivating Forkhead transcription factors, Akt inhibits transcription of the cell cycle inhibitor p27/KIP1.It also blocks the anti-proliferative actions of p21 and p27, preventing them from entering the nucleus. Furthermore, because Akt blocks glycogen synthase kinase-3 (GSK3), it blocks -catenin breakdown directly (Dasgupta&Gutmann, 2003; Sonoda et al., 2001; Zhao et al., 2016).

Stabilized -catenin promotes the production of pro-proliferative target genes including cyclin D1 and c-Myc once it enters the nucleus. Akt (protein kinase B), a serine-threonine protein kinase that is involved in phosphoinositide-3-kinase-mediated signaling, is another possible treatment target (Joensuu et al., 2005; Kaley et al., 2019; Lim et al., 2004; Verhaak et al., 2010). Its activation has been linked to the survival of prostate cancer cells as well as the evolution of castration resistance and chemotherapy resistance (Nesterov et al. 2001).

Sorafenib has proven efficacy against a broad-spectrum activity against numerous preclinical models of human cancer due to its large range of molecular targets (Itoh &Ornitz, 2004; X. Li & Gao, 2014; S. I. Wang et al., 1997). In hepatocellular carcinoma, melanoma and breast cancer, malignant glioma, leukemia, and medulloblastoma, sorafenib has been shown to decrease cell growth or cause apoptosis, according to studies. In a dose-dependent way, our cell viability experiment revealed that sorafenib had a comparable effect on SK-N-AS, a commonly utilized neuroblastoma cell line (Fenstermaker&Ciesielski, 2014; Gutin et al., 2009; Höland et al., 2014).

Due to a loss or mutation of the PTEN tumor suppressor gene, Akt is commonly activated in advanced prostate cancer (Sircar et al. 2009).Hyperactivity of Akt has been linked to high preoperative PSA levels, higher Gleason grades, shorter relapses, and treatment resistance in clinical and preclinical investigations (Sircar et al.2009). Activated Akt phosphorylates and inactivates glycogen synthase kinase-3b, a downstream target (GSK-3b). As a result of GSK-3b-

mediated phosphorylation of MCL-1, it binds to the E3 ligase b-TrCP and is degraded by the proteasome. Furthermore, Akt activity has recently been shown to favorably influence AR protein levels (Ha et al. 2011). Sorafenib is a multikinase blocker that was first designed to inhibit Raf kinase, a well-studied serinethreonine kinase that regulates cell survival (Wilhelm et al. 2004). Sorafenib has been found to target a variety of neoangiogenesis-related receptor tyrosine kinases, including VGFR, PDGFR, FLT3, Ret, and c-Kit (Wilhelm et al. 2004). Furthermore, sorafenib is found to cause apoptosis in numerous human cancer cell lines by suppressing the exposure of a protein called caspase 3. Sorafenib is authorized to treat hepatocellular and renal cell carcinoma and has shown promising preclinical efficacy against several tumor types (Kane et al. 2006, Lang 2008). Sorafenib therapy in conjunction with antiangiogenic medicines in CRPC has been found to have a favorable effect in clinical trials (Steinbild et al. 2007, Chi et al. 2008, Dahut et al. 2008). Although sorafenib is in phase II clinical trials for the treatment of prostate cancer, the molecular processes that occur when its targets are inhibited and the apoptotic pathways are regulated have not been well investigated (Rajani et al., 2019; Walton et al., 2018; Weller et al., 2017).

Chapter 6:

Discussion

GBM may be a precarious sickness with a disheartening Expectation, and elective medicines are necessary to work on the Visualization for patients. Genomic examinations of GBM revealed several dysregulations of key cell hailing pathways that Set up engaging centers for treatment. Centering on individual Parts of these pathways utilizing small molecule blockers, What's more, antibodies have given fluctuating degrees of accomplishment within the Treatment of GBM. Thus, it may well be more beneficial to center on various components of diverse hailing pathways, to Slaughter GBM. Moreover, cancer cells are Heterogeneous, and centering on the process that's centered on diverse Pathways would contain a more capable treatment. Various Medications also disregard to have profitable impacts since of the blood–Mind obstacle and the nearness of energetic efflux siphons that forbear Medicine segment into the intellect. (Baik et al., 2015). The pharmaceutical Carriers P-glycoprotein and bosom threat obstacle Proteins have been shown to decrease intellect invasion of Erlotinib clarifying the moderately helpless results found within the GBM Setting (De Vries et al., 2012). Later progresses in nanoparticle movement of drugs have Engaged the transport of solutions already unequipped for crossing point the Blood–cerebrum obstacle, arrive at the intellect parenchyma and in this way, enable Effective centering of intracranial tumors (Steiniger et al., 2004). The blend of centered ultrasound with smaller scale bubbles has furthermore been shown to Allow drugs to invade the BBB (H. L. Liu et al., 2010). This Strategy might allow AKT inhibitors to cross the blood–mind Boundary all the more successfully and hence overhaul their assets.

As of late, twists in qualities and sub-atomic pathways in GBMs have given a characteristic preface to set up fitting clinically critical biomarkers and highlight the required progression of unused

medicinal opportunities. We are at a point where advance in nuclear characterization of GBMs has given supportive encounters to the advancement of more effective assigned therapeutics. Some clinically relevant atomic markers are grounded and serve within the center as the standard of care for patients who decided to have Glioma cancers. For occurrence, the circumstance with MGMT sponsor Methylation in GBMs (especially those recognized in ancient patients), 1p and 19q co-erasures in anaplastic oligoden-drogliomas, and IDH1/2 changes, directly accept noteworthy parts in cancer diagnostics or possibly clinical energetic (Cairncross et al., 2013), (Reardon et al., 2011), (W. Wick et al., 2012). Within the between times, multiplatform examinations of the genetic, epigenetic, and transcriptional profiles have illustrated supportive in refining the course of action of cerebrum cancers and foreseeing persistent results.

Late examinations on pediatric GBM have appeared that these cancers, which are each presently and againdriven by epigenetic changes in histone H3.3, may speak to a third noteworthy lesson of GBM, regardless of IDH1/2 crack (discretionary) and IDH1/2 wild-type (fundamental) GBMs in grown-ups. With these nuclear bits of information, it is trusted that covering up their upgrades in nuclear measures would bring them to the center and be sought after as clinically appeared. These strategies may sometimes recently long turn out to be all the more by and large advantage competent, less difficult to normalize, and turn out to be savvier.Other than that, the current histology-based finding of cerebrum developments will dynamically be improved with nuclear demonstrative tests to engage a science-based characterization and advance create an understanding outline that will in a perfect world be joined in carefully arranged clinical preliminaries. It is trusted that this strategy of precision diagnostics–therapeutics can lead to bit-by-bit upgrades of results where compelling therapeutics are legitimately "facilitated" with molecularly characterized understanding subsets. Without a doubt, indeed with the current

energize in nuclear characterization, we remain a tremendous separate from significant overhauls, and at final a settle, for patients with GBM. Suitable characterization and bio-rationale understanding, whereas an imperative component of customized treatment, is fair a single portion and in itself is of confined regard but in case facilitated by break even with achievements within the make of companion solutions and modalities for the by and large talking objective of worked on calm comes about. Sorafenib appears as an appealing accommodating elective in HGG because it controls several naturally appropriate oncogenic pathways and applies an underhanded antitumor effect by hindering angiogenesis. Until this point in time, limited information about sorafenib in patients with irregularities has been found.

(F. F. Lang et al., 2018). Presented an organized I parcel increasing survey to the MTD of sorafenib in patients with discontinuous destructive tumors. Their choice was that sorafenib was well Persevered with limited harm levels up to doses of 800 mg twice each day in patients without concurrent compound Actuating anticonvulsant drugs (EIAEDs). Within the survey By Nabors et al. [9] in 2011, the final sentence is as per the taking after: 'In the setting of intensely pretreated patients, sorafenib Need to be considered for extra appraisal given the straightforwardness Of organization, unremarkable accidental impact profile, and favor- Competent pharmacokinetics at the MTD set up by this Study'. In any case, the survey needs reasonability data.

The treatment of GBM keeps on being an intricate and troublesome test. Past endeavors to discover A fix have just brought about a slight improvement in endurance throughout the most recent 50 years, as the current 5-year Endurance rate stays low at <10% (Stupp et al., 2009). As some limitations on the events the present Therapeutic technique of restorative method, radiotherapy, and chemotherapy can be used, the leading book Supportive master or treatment tradition, as a component of a multimodal method, ought to capacity to require out any waiting development.

Inevitably, this may well be fulfilled by the synergistic impacts of joining several present therapeutic processes quickly outlined in this article, counting an assigned treatment, Immunotherapy, chemotherapy, or radiotherapy, as treatment restriction might conceivably make to a singular treatment. The enhancement of modern and novel medications has been backed by the broad Endeavors to unwind the genomic scene of GBM with the headway of cutting edge sequencing, Inciting alterations in cancer course of action, and the 'atomic' clinical organization of a couple of GBM patients.

After a few times, the therapeutic strategies will increase with more targetable and vital Blends of genomic changes and adjustments being unexamined, as fair a small portion to date have been appeared to have clinical execution. Altogether, as cancer heterogeneity and Patient-to-patient changeability including the advancement of GBM and reaction to treatment is driven by The genomics of each development, a customized treatment approach through the definition of patients Into sub-atomic subgroups will be essential in their task to the foremost suitable new treatment Technique that will be available afterward on the organization of GBM. The continued participation between Investigators and clinicians, combined with movements in development, both tentatively and clinically, suits a cheerful future that modern and capable drugs will be created for GBM patients.

Chapter 7:

Conclusion

Current glioma treatment choices are constrained, and given current regimens' moo survival rates, the number of choices must be extended. Hindrance of phosphor-AKT is a zone of glioma treatment that hasn't gotten much consideration. Overexpression of AKT and resulting downstream signaling are the conclusion comes about of numerous of the hereditary anomalies regularly watched in glioblastoma tumors. If AKT signaling can be blocked, fundamental oncogenic exercises counting cell multiplication, intrusion, and apoptosis blocking might all be tended to at the same time. Restraint of upstream and downstream effectors, in expansion to coordinate hindrance of AKT, may well be considered encourage as restorative strategies. Since AKT actuation is basic for glioma cell multiplication and intrusion, it ought to be explored in advance utilizing precise in vitro and in vivo glioma models in arrange to progress the number of successful medicines for glioma patients.

Chapter 8:

Future Work

The blood-brain barrier, which is a physiologic barrier to medicine transport to the central nervous system, complicates glioma treatment. For the local delivery of medications to brain tumors, many techniques have been explored, including convection-enhanced delivery. As a result, local distribution of sorafenib to malignant brain cells may result in more effective anticancer action with less systemic damage. Clinical studies with numerous types of solid tumors have shown that sorafenib has acceptable tolerability and potential anticancer efficacy. As a result, sorafenib has the potential to be a viable therapy for malignant gliomas. If there is a chance of experimenting with sorafenib on a large scale, then there is the possibility to find out the actual results of sorafenib foruse to treat GBM. However, sorafenib is not officially approved for the treatment of GBM but it has shown tremendous results in the treatment of HCC. Advanced drug delivery technology can take Sorafenib at a higher level where it can be used harmlessly in the treatment of GBM.

Despite this synergistic impact, the blood-brain barrier (BBB), a physiological barrier to medication transport to the central nervous system, complicates the treatment of glioma. It's yet unknown how TTFields affect the BBB. Sorafenib delivered locally to malignant cells in the brain might boost anticancer activity while lowering systemic toxicity. As a result, when combined with TTFields, sorafenib might be a viable treatment for malignant gliomas. Clinical studies of tumor therapies based on electric fields must be improved.Clinical trials of electric field-based tumor therapies must be optimized through preclinical research utilizing patient samples and the use of electric fields alone or in conjunction with medications. Despite multiple Sorafenib clinical studies for other solid tumors, interest in GBM clinical trials remains low.Glioma patients, on the other hand, have few treatment choices, the majority of which are palliative. The findings of this study

imply that using sorafenib for inhibiting the AKT pathway which helps the tumor cells to proliferate inthe treatment of GBM. Sorafenib can also be used to treat tumors such as renal cell carcinoma, hepatocellular carcinoma, and thyroid cancer. As a result, in practical practice, a combination of sorafenib to inhibit the Akt pathway may be useful in treating certain malignancies.

References:

Adeberg, S., Bernhardt, D., Harrabi, S. Ben, Bostel, T., Mohr, A., Koelsche, C., Diehl, C., Rieken, S., & Debus, J. (2015). Metforminbeeinflusst die Progression beidiabetischenGlioblastompatienten. *Strahlentherapie Und Onkologie*, *191*(12), 928–935. https://doi.org/10.1007/s00066-015-0884-5

Agliardi, G., Liuzzi, A. R., Hotblack, A., De Feo, D., Núñez, N., Stowe, C. L., Friebel, E., Nannini, F., Rindlisbacher, L., Roberts, T. A., Ramasawmy, R., Williams, I. P., Siow, B. M., Lythgoe, M. F., Kalber, T. L., Quezada, S. A., Pule, M. A., Tugues, S., Straathof, K., & Becher, B. (2021). Intratumoral IL-12 delivery empowers CAR-T cell immunotherapy in a pre-clinical model of glioblastoma. *Nature Communications*, *12*(1), 1–11. https://doi.org/10.1038/s41467-020-20599-x

Ahmadov, U., Picard, D., Bartl, J., Silginer, M., Trajkovic-Arsic, M., Qin, N., Blümel, L., Wolter, M., Lim, J. K. M., Pauck, D., Winkelkotte, A. M., Melcher, M., Langini, M., Marquardt, V., Sander, F., Stefanski, A., Steltgens, S., Hassiepen, C., Kaufhold, A., … Remke, M. (2021). The long non-coding RNA HOTAIRM1 promotes tumor aggressiveness and radiotherapy resistance in glioblastoma. *Cell Death & Disease*, *12*(10), 1–11. https://doi.org/10.1038/s41419-021-04146-0

Akbari, H., Kazerooni, A. F., Ware, J. B., Mamourian, E., Anderson, H., Guiry, S., Sako, C., Raymond, C., Yao, J., Brem, S., O'Rourke, D. M., Desai, A. S., Bagley, S. J., Ellingson, B. M., Davatzikos, C., &Nabavizadeh, A. (2021). Quantification of tumor microenvironment acidity in glioblastoma using principal component analysis of dynamic susceptibility contrast-enhanced MR imaging. *Scientific Reports*, *11*(1), 1–8. https://doi.org/10.1038/s41598-021-94560-3

Alexander, B. M., Ba, S., Berger, M. S., Berry, D. A., Cavenee, W. K., Chang, S. M., Cloughesy, T. F., Jiang, T., Khasraw, M., Li, W., Mittman, R., Poste, G. H., Wen, P. Y., Alfred Yung, W. K., Barker, A. D., David Adelson, P., Alexander, B. M., Alper, J., Arnold, M. M., … Quackenbush, J. (2018). An adaptive global innovative learning environment for glioblastoma: GBM AGILE. *Clinical Cancer Research*, *24*(4), 737–743. https://doi.org/10.1158/1078-0432.CCR-17-0764

Álvarez-Garcia, V., Tawil, Y., Wise, H. M., & Leslie, N. R. (2019). Mechanisms of PTEN loss in cancer: It's all about diversity. *Seminars in Cancer Biology*, *59*, 66–79. https://doi.org/10.1016/j.semcancer.2019.02.001

Amirian, E. S., Armstrong, G. N., Zhou, R., Lau, C. C., Claus, E. B., Barnholtz-Sloan, J. S., Il'Yasova, D., Schildkraut, J., Ali-Osman, F., Sadetzki, S., Johansen, C., Houlston, R. S., Jenkins, R. B., Lachance, D., Olson, S. H., Bernstein, J. L., Merrell, R. T., Wrensch, M. R., Davis, F. G., … Bondy, M. L. (2016). The Glioma International Case-Control Study: A Report from the Genetic Epidemiology of Glioma International Consortium. *American Journal of Epidemiology*, *183*(2), 85–91. https://doi.org/10.1093/aje/kwv235

Anandharaj, A., Cinghu, S., & Park, W. Y. (2011). Rapamycin-mediated mTOR inhibition attenuates survivin and sensitizes glioblastoma cells to radiation therapy. *ActaBiochimica et BiophysicaSinica*, *43*(4), 292–300. https://doi.org/10.1093/abbs/gmr012

Baba, K., Mizumoto, M., Oshiro, Y., Shimizu, S., Nakamura, M., Hiroshima, Y., Iizumi, T., Saito, T., Numajiri, H., Nakai, K., Ishikawa, H., Okumura, T., Maruo, K., & Sakurai, H. (2021). An analysis of vertebral body growth after proton beam therapy for pediatric cancer. *Cancers*, *13*(2), 1–10. https://doi.org/10.3390/cancers13020349

Bagley, S. J., Desai, A. S., Linette, G. P., June, C. H., & O'Rourke, D. M. (2018). CAR T-cell therapy for glioblastoma: Recent clinical advances and future challenges. *Neuro-Oncology*, *20*(11), 1429–1438. https://doi.org/10.1093/neuonc/noy032

Bai, D., Ueno, L., & Vogt, P. K. (2009). Akt-mediated regulation of NFκB and the essentialness of NFκB for the oncogenicity of PI3K and Akt. *International Journal of Cancer*, *125*(12), 2863–2870. https://doi.org/10.1002/ijc.24748

Baik, C. S., Chamberlain, M. C., & Chow, L. Q. (2015). Targeted Therapy for Brain Metastases in EGFR-Mutated and ALK-Rearranged Non-Small-Cell Lung Cancer. *Journal of Thoracic Oncology*, *10*(9), 1268–1278. https://doi.org/10.1097/JTO.0000000000000615

Balli, D., Zhang, Y., Snyder, J., Kalinichenko, V. V., & Kalin, T. V. (2011). Endothelial cell-specific deletion of transcription factor foxM1 increases urethane-induced lung carcinogenesis. *Cancer Research*, *71*(1), 40–50. https://doi.org/10.1158/0008-5472.CAN-10-2004

Barekatain, Y., Ackroyd, J. J., Yan, V. C., Khadka, S., Wang, L., Chen, K. C., Portal, A. H., Tran, T., Georgiou, D. K., Arthur, K., Lin, Y. H., Satani, N., Ballato, E. S., Behr, E. I., deCarvalho, A. C., Verhaak, R. G. W., de Groot, J., Huse, J. T., Asara, J. M., … Muller, F. L. (2021). Homozygous MTAP deletion in primary human glioblastoma is not associated with the elevation of methylthioadenosine. *Nature Communications*, *12*(1), 1–13. https://doi.org/10.1038/s41467-021-24240-3

Benitez, J. A., Ma, J., D'Antonio, M., Boyer, A., Camargo, M. F., Zanca, C., Kelly, S., Khodadadi-Jamayran, A., Jameson, N. M., Andersen, M., Miletic, H., Saberi, S., Frazer, K. A., Cavenee, W. K., &Furnari, F. B. (2017). PTEN regulates glioblastoma oncogenesis through chromatin-associated complexes of DAXX and histone H3.3. *Nature Communications*, *8*(May), 1–14. https://doi.org/10.1038/ncomms15223

Benitez, J. A., Ma, J., D'Antonio, M., Boyer, A., Camargo, M. F., Zanca, C., Kelly, S., Khodadadi-Jamayran, A., Jameson, N. M., Andersen, M., Miletic, H., Saberi, S., Frazer, K. A., Cavenee, W. K., &Furnari, F. B. (2018). Publisher Correction: PTEN regulates glioblastoma oncogenesis through chromatin-associated complexes of DAXX and histone H3.3 (Nature Communications (2017) 8 (15223) DOI: 10.1038/ncomms15223). *Nature Communications*, *9*, 1. https://doi.org/10.1038/ncomms16217

Beug, S. T., Beauregard, C. E., Healy, C., Sanda, T., St-Jean, M., Chabot, J., Walker, D. E., Mohan, A., Earl, N., Lun, X., Senger, D. L., Robbins, S. M., Staeheli, P., Forsyth, P. A., Alain, T., Lacasse, E.

C., &Korneluk, R. G. (2017). Smacmimetics synergize with immune checkpoint inhibitors to promote tumour immunity against glioblastoma. *Nature Communications*, *8*. https://doi.org/10.1038/ncomms14278

Beug, S. T., Beauregard, C. E., Healy, C., Sanda, T., St-Jean, M., Chabot, J., Walker, D. E., Mohan, A., Earl, N., Lun, X., Senger, D. L., Robbins, S. M., Staeheli, P., Forsyth, P. A., Alain, T., Lacasse, E. C., &Korneluk, R. G. (2018). Publisher Correction: Smacmimetics synergize with immune checkpoint inhibitors to promote tumour immunity against glioblastoma (Nature Communications (2017) 8 (14278) DOI: 10.1038/ncomms14278). *Nature Communications*, *9*, 1. https://doi.org/10.1038/ncomms16231

Binder, S., Zipfel, I., Müller, C., Wiedemann, K., Schimmelpfennig, C., Pfeifer, G., Reiche, K., Hauschildt, S., Lehmann, J., Köhl, U., Horn, F., & Friedrich, M. (2021). The noncoding RNA LINC00152 conveys contradicting effects in different glioblastoma cells. *Scientific Reports*, *11*(1), 1–10. https://doi.org/10.1038/s41598-021-97533-8

Bloch, O., Crane, C. A., Fuks, Y., Kaur, R., Aghi, M. K., Berger, M. S., Butowski, N. A., Chang, S. M., Clarke, J. L., McDermott, M. W., Prados, M. D., Sloan, A. E., Bruce, J. N., &Parsa, A. T. (2014). Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: A phase II, single-arm trial. *Neuro-Oncology*, *16*(2), 274–279. https://doi.org/10.1093/neuonc/not203

Bobustuc, G. C., Baker, C. H., Limaye, A., Jenkins, W. D., Pearl, G., Avgeropoulos, N. G., &Konduri, S. D. (2010). Levetiracetam enhances p53-mediated MGMT inhibition and sensitizes glioblastoma cells to temozolomide. *Neuro-Oncology*, *12*(9), 917–927. https://doi.org/10.1093/neuonc/noq044

Brenner, A. J., Floyd, J., Fichtel, L., Michalek, J., Kanakia, K. P., Huang, S., Reardon, D., Wen, P. Y., & Lee, E. Q. (2021). Phase 2 trial of hypoxia activated evofosfamide (TH302) for treatment of recurrent bevacizumab-refractory glioblastoma. *Scientific Reports*, *11*(1), 1–6. https://doi.org/10.1038/s41598-021-81841-0

Brooks, L. J., Clements, M. P., Burden, J. J., Kocher, D., Richards, L., Devesa, S. C., Zakka, L., Woodberry, M., Ellis, M., Jaunmuktane, Z., Brandner, S., Morrison, G., Pollard, S. M., Dirks, P. B., Marguerat, S., &Parrinello, S. (2021). The white matter is a pro-differentiative niche for glioblastoma. *Nature Communications*, *12*(1). https://doi.org/10.1038/s41467-021-22225-w

Bruix, J., & Sherman, M. (2011). Management of hepatocellular carcinoma: An update. *Hepatology*, *53*(3), 1020–1022. https://doi.org/10.1002/hep.24199

Burris, H. A. (2013). Overcoming acquired resistance to anticancer therapy: Focus on the PI3K/AKT/mTOR pathway. *Cancer Chemotherapy and Pharmacology*, *71*(4), 829–842. https://doi.org/10.1007/s00280-012-2043-3

Cabrera, A. R., Kirkpatrick, J. P., Fiveash, J. B., Shih, H. A., Koay, E. J., Lutz, S., Petit, J., Chao, S. T., Brown, P. D., Vogelbaum, M., Reardon, D. A., Chakravarti, A., Wen, P. Y., & Chang, E. (2016). Radiation therapy for glioblastoma: Executive summary of an American Society for Radiation Oncology Evidence-Based Clinical Practice Guideline. *Practical Radiation Oncology*, *6*(4), 217–225. https://doi.org/10.1016/j.prro.2016.03.007

Cairncross, G., Wang, M., Shaw, E., Jenkins, R., Brachman, D., Buckner, J., Fink, K., Souhami, L., Laperriere, N., Curran, W., & Mehta, M. (2013). Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: Long-term results of RTOG 9402. *Journal of Clinical Oncology*, *31*(3), 337–343. https://doi.org/10.1200/JCO.2012.43.2674

Cantanhede, I. G., & De Oliveira, J. R. M. (2017). PDGF Family Expression in Glioblastoma Multiforme: Data Compilation from Ivy Glioblastoma Atlas Project Database. *Scientific Reports*, *7*(1), 1–9. https://doi.org/10.1038/s41598-017-15045-w

Carra, E., Barbieri, F., Marubbi, D., Pattarozzi, A., Favoni, R. E., Florio, T., &Daga, A. (2013). Sorafenib selectively depletes human glioblastoma tumor-initiating cells from primary cultures. *Cell Cycle*, *12*(3), 491–500. https://doi.org/10.4161/cc.23372

Carracedo, A., &Pandolfi, P. P. (2008). The PTEN-PI3K pathway: Of feedbacks and cross-talks. *Oncogene*, *27*(41), 5527–5541. https://doi.org/10.1038/onc.2008.247

Carvalho, B., Lopes, J. M., Silva, R., Peixoto, J., Leitão, D., Soares, P., Fernandes, A. C., Linhares, P., Vaz, R., & Lima, J. (2021). The role of c-Met and VEGFR2 in glioblastoma resistance to bevacizumab. *Scientific Reports*, *11*(1), 1–8. https://doi.org/10.1038/s41598-021-85385-1

Celiku, O., Gilbert, M. R., &Lavi, O. (2019). Computational modeling demonstrates that glioblastoma cells can survive spatial environmental challenges through exploratory adaptation. *Nature Communications*, *10*(1). https://doi.org/10.1038/s41467-019-13726-w

Chamberlain, M. C. (2014). Is there a role for vaccine-based therapy in recurrent glioblastoma? *Neuro-Oncology*, *16*(5), 757. https://doi.org/10.1093/neuonc/nou031

Chojak, R., Koźba-Gosztyła, M., Słychan, K., Gajos, D., Kotas, M., Tyliszczak, M., &Czapiga, B. (2021). Impact of surgical resection of butterfly glioblastoma on survival: a meta-analysis based on comparative studies. *Scientific Reports*, *11*(1), 1–7. https://doi.org/10.1038/s41598-021-93441-z

Clavreul, A., Roger, E., Pourbaghi-Masouleh, M., Lemaire, L., Tétaud, C., &Menei, P. (2018). Development and characterization of sorafenib-loaded lipid nanocapsules for the treatment of glioblastoma. *Drug Delivery*, *25*(1), 1756–1765. https://doi.org/10.1080/10717544.2018.1507061

Cloughesy, T. F., Mochizuki, A. Y., Orpilla, J. R., Hugo, W., Lee, A. H., Davidson, T. B., Wang, A. C., Ellingson, B. M., Rytlewski, J. A., Sanders, C. M., Kawaguchi, E. S., Du, L., Li, G., Yong, W. H., Gaffey, S. C., Cohen, A. L., Mellinghoff, I. K., Lee, E. Q., Reardon, D. A., … Prins, R. M. (2019). Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. *Nature Medicine*, *25*(3), 477–486. https://doi.org/10.1038/s41591-018-0337-7

Cohen, A. L., Holmen, S. L., & Colman, H. (2013). IDH1 and IDH2 mutations in gliomas. *Current Neurology and Neuroscience Reports*, *13*(5), 1–7. https://doi.org/10.1007/s11910-013-0345-4

Couturier, C. P., Ayyadhury, S., Le, P. U., Nadaf, J., Monlong, J., Riva, G., Allache, R., Baig, S., Yan, X., Bourgey, M., Lee, C., Wang, Y. C. D., Yong, V. W., Guiot, M. C., Najafabadi, H., Misic, B., Antel, J., Bourque, G., Ragoussis, J., &Petrecca, K. (2020). Author Correction: Single-cell RNA-seq reveals that glioblastoma recapitulates a normal neurodevelopmental hierarchy (Nature Communications, (2020), 11, 1, (3406), 10.1038/s41467-020-17186-5). *Nature Communications*, *11*(1), 41467. https://doi.org/10.1038/s41467-020-17979-8

Cui, Q., Yang, S., Ye, P., Tian, E., Sun, G., Zhou, J., Sun, G., Liu, X., Chen, C., Murai, K., Zhao, C., Azizian, K. T., Yang, L., Warden, C., Wu, X., D'Apuzzo, M., Brown, C., Badie, B., Peng, L., … Shi, Y. (2016). Downregulation of TLX induces TET3 expression and inhibits glioblastoma stem cell self-renewal and tumorigenesis. *Nature Communications*, *7*. https://doi.org/10.1038/ncomms10637

D'Alessio, A., Proietti, G., Sica, G., &Scicchitano, B. M. (2019). Pathological and molecular features of glioblastoma and its peritumoral tissue. *Cancers*, *11*(4). https://doi.org/10.3390/cancers11040469

Dadey, D. Y. A., Kapoor, V., Hoye, K., Khudanyan, A., Collins, A., Thotala, D., & Hallahan, D. E. (2017). Antibody targeting GRP78 enhances the efficacy of radiation therapy in human glioblastoma and non-small cell lung cancer cell lines and tumor models. *Clinical Cancer Research*, *23*(10), 2556–2564. https://doi.org/10.1158/1078-0432.CCR-16-1935

Dadras, M. S., Caja, L., Mezheyeuski, A., Liu, S., Gélabert, C., Gomez-Puerto, M. C., Gallini, R., Rubin, C.-J., Ten Dijke, P., Heldin, C.-H., & Moustakas, A. (2021). The polarity protein Par3 coordinates positively self-renewal and negatively invasiveness in glioblastoma. *Cell Death & Disease*, *Accepted*(August 2020). https://doi.org/10.1038/s41419-021-04220-7

Dasgupta, B., & Gutmann, D. H. (2003). Neurofibromatosis 1: Closing the GAP between mice and men. *Current Opinion in Genetics and Development*, *13*(1), 20–27. https://doi.org/10.1016/S0959-437X(02)00015-1

Daubon, T., Léon, C., Clarke, K., Andrique, L., Salabert, L., Darbo, E., Pineau, R., Guérit, S., Maitre, M., Dedieu, S., Jeanne, A., Bailly, S., Feige, J. J., Miletic, H., Rossi, M., Bello, L., Falciani, F., Bjerkvig, R., &Bikfalvi, A. (2019). Deciphering the complex role of thrombospondin-1 in glioblastoma development. *Nature Communications*, *10*(1). https://doi.org/10.1038/s41467-019-08480-y

Davies, A. M., Weinberg, U., &Palti, Y. (2013). Tumor treating fields: A new frontier in cancer therapy. *Annals of the New York Academy of Sciences*, *1291*(1), 86–95. https://doi.org/10.1111/nyas.12112

De Vries, N. A., Buckle, T., Zhao, J., Beijnen, J. H., Schellens, J. H. M., & Van Tellingen, O. (2012). Restricted brain penetration of the tyrosine kinase inhibitor erlotinib due to the drug transporters P-gp and BCRP. *Investigational New Drugs*, *30*(2), 443–449. https://doi.org/10.1007/s10637-010-9569-1

Dong, F., Li, Q., Yang, C., Huo, D., Wang, X., Ai, C., Kong, Y., Sun, X., Wang, W., Zhou, Y., Liu, X., Li, W., Gao, W., Liu, W., Kang, C., & Wu, X. (2018). PRMT2 links histone H3R8 asymmetric dimethylation to oncogenic activation and tumorigenesis of glioblastoma. *Nature Communications*, *9*(1), 1–14. https://doi.org/10.1038/s41467-018-06968-7

Elshafeey, N., Kotrotsou, A., Hassan, A., Elshafei, N., Hassan, I., Ahmed, S., Abrol, S., Agarwal, A., El Salek, K., Bergamaschi, S., Acharya, J., Moron, F. E., Law, M., Fuller, G. N., Huse, J. T., Zinn, P. O., &Colen, R. R. (2019). Multicenter study demonstrates radiomic features derived from magnetic resonance perfusion images identify pseudoprogression in glioblastoma. *Nature Communications*, *10*(1), 1–9. https://doi.org/10.1038/s41467-019-11007-0

Fang, R., Chen, X., Zhang, S., Shi, H., Ye, Y., Shi, H., Zou, Z., Li, P., Guo, Q., Ma, L., He, C., & Huang, S. (2021). EGFR/SRC/ERK-stabilized YTHDF2 promotes cholesterol dysregulation and invasive growth of glioblastoma. *Nature Communications*, *12*(1). https://doi.org/10.1038/s41467-020-20379-7

Fang, X., Yu, S. X., Lu, Y., Bast, R. C., Woodgett, J. R., & Mills, G. B. (2000). Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A. *Proceedings of the National Academy of Sciences of the United States of America*, *97*(22), 11960–11965. https://doi.org/10.1073/pnas.220413597

Fenstermaker, R. A., & Ciesielski, M. J. (2014). Challenges in the development of a survivin vaccine (SurVaxM) for malignant glioma. *Expert Review of Vaccines*, *13*(3), 377–385. https://doi.org/10.1586/14760584.2014.881255

Fenstermaker, R. A., Ciesielski, M. J., Qiu, J., Yang, N., Frank, C. L., Lee, K. P., Mechtler, L. R., Belal, A., Ahluwalia, M. S., & Hutson, A. D. (2016). Clinical study of a survivin long peptide vaccine (SurVaxM) in patients with recurrent malignant glioma. *Cancer Immunology, Immunotherapy*, *65*(11), 1339–1352. https://doi.org/10.1007/s00262-016-1890-x

Fogh, S. E., Andrews, D. W., Glass, J., Curran, W., Glass, C., Champ, C., Evans, J. J., Hyslop, T., Pequignot, E., Downes, B., Comber, E., Maltenfort, M., Dicker, A. P., & Werner-Wasik, M. (2010). Hypofractionated stereotactic radiation therapy: An effective therapy for recurrent high-grade gliomas. *Journal of Clinical Oncology*, *28*(18), 3048–3053. https://doi.org/10.1200/JCO.2009.25.6941

Gallia, G. L., Tyler, B. M., Hann, C. L., Siu, I. M., Giranda, V. L., Vescovi, A. L., Brem, H., & Riggins, G. J. (2009). Inhibition of Akt inhibits growth of glioblastoma and glioblastoma stem-like cells. *Molecular Cancer Therapeutics*, *8*(2), 386–393. https://doi.org/10.1158/1535-7163.MCT-08-0680

Gottardo, N. G., &Gajjar, A. (2006). *Medulloblastoma*.

Gregory, J. V., Kadiyala, P., Doherty, R., Cadena, M., Habeel, S., Ruoslahti, E., Lowenstein, P. R., Castro, M. G., &Lahann, J. (2020). Systemic brain tumor delivery of synthetic protein nanoparticles for glioblastoma therapy. *Nature Communications*, *11*(1), 1–15. https://doi.org/10.1038/s41467-020-19225-7

Grossman, S. A., Ye, X., Chamberlain, M., Mikkelsen, T., Batchelor, T., Desideri, S., Piantadosi, S., Fisher, J., & Fine, H. A. (2009). Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma: A multicenter phase II trial. *Journal of Clinical Oncology*, *27*(25), 4155–4161. https://doi.org/10.1200/JCO.2008.21.6895

Guo, D., Prins, R. M., Dang, J., Kuga, D., Iwanami, A., Soto, H., Lin, K. Y., Huang, T. T., Akhavan, D., Hock, M. B., Zhu, S., Kofman, A. A., Bensinger, S. J., Yong, W. H., Vinters, H. V., Horvath, S., Watson, A. D., Kuhn, J. G., Robins, H. I., … Mischel, P. S. (2009). EGFR signaling through an Akt-

SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy. *Science Signaling*, *2*(101), 1–12. https://doi.org/10.1126/scisignal.2000446

Gutin, P. H., Iwamoto, F. M., Beal, K., Mohile, N. A., Karimi, S., Hou, B. L., Lymberis, S., Yamada, Y., Chang, J., &Abrey, L. E. (2009). Safety and Efficacy of Bevacizumab With Hypofractionated Stereotactic Irradiation for Recurrent Malignant Gliomas. *International Journal of Radiation Oncology Biology Physics*, *75*(1), 156–163. https://doi.org/10.1016/j.ijrobp.2008.10.043

Hahn, O., & Stadler, W. (n.d.). *Sorafenib*. *2*, 615–621.

Hainsworth, J. D., Ervin, T., Friedman, E., Priego, V., Murphy, P. B., Clark, B. L., & Lamar, R. E. (2010). Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme. *Cancer*, *116*(15), 3663–3669. https://doi.org/10.1002/cncr.25275

Happold, C., Gorlia, T., Chinot, O., Gilbert, M. R., Nabors, L. B., Wick, W., Pugh, S. L., Hegi, M., Cloughesy, T., Roth, P., Reardon, D. A., Perry, J. R., Mehta, M. P., Stupp, R., & Weller, M. (2016). Does valproic acid or levetiracetam improve survival in glioblastoma? A pooled analysis of prospective clinical trials in newly diagnosed glioblastoma. *Journal of Clinical Oncology*, *34*(7), 731–739. https://doi.org/10.1200/JCO.2015.63.6563

Hasselbalch, B., Lassen, U., Hansen, S., Holmberg, M., Soørensen, M., Kosteljanetz, M., Broholm, H., Stockhausen, M. T., & Poulsen, H. S. (2010). Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: A phase II trial. *Neuro-Oncology*, *12*(5), 508–516. https://doi.org/10.1093/neuonc/nop063

Hatori, M., Hosaka, M., Watanabe, M., Moriya, T., Sasano, H., &Kokubun, S. (2006). Osteosarcoma in a patient with neurofibromatosis type 1: A case report and review of the literature. *Tohoku Journal of Experimental Medicine*, *208*(4), 343–348. https://doi.org/10.1620/tjem.208.343

Hegi, M. E., Diserens, A. C., Bady, P., Kamoshima, Y., Kouwenhoven, M. C. M., Delorenzi, M., Lambiv, W. L., Hamou, M. F., Matter, M. S., Koch, A., Heppner, F. L., Yonekawa, Y., Merlo, A., Frei, K., Mariani, L., & Hofer, S. (2011). Pathway analysis of glioblastoma tissue after preoperative treatment with the EGFR tyrosine kinase inhibitor gefitinib - A phase II trial. *Molecular Cancer Therapeutics*, *10*(6), 1102–1112. https://doi.org/10.1158/1535-7163.MCT-11-0048

Henrik Heiland, D., Ravi, V. M., Behringer, S. P., Frenking, J. H., Wurm, J., Joseph, K., Garrelfs, N. W. C., Strähle, J., Heynckes, S., Grauvogel, J., Franco, P., Mader, I., Schneider, M., Potthoff, A. L., Delev, D., Hofmann, U. G., Fung, C., Beck, J., Sankowski, R., … Schnell, O. (2019). Tumor-

associated reactive astrocytes aid the evolution of immunosuppressive environment in glioblastoma. *Nature Communications*, *10*(1). https://doi.org/10.1038/s41467-019-10493-6

Herviou, P., Le Bras, M., Dumas, L., Hieblot, C., Gilhodes, J., Cioci, G., Hugnot, J. P., Ameadan, A., Guillonneau, F., Dassi, E., Cammas, A., &Millevoi, S. (2020). hnRNP H/F drive RNA G-quadruplex-mediated translation linked to genomic instability and therapy resistance in glioblastoma. *Nature Communications*, *11*(1), 1–17. https://doi.org/10.1038/s41467-020-16168-x

Herviou, P., Le Bras, M., Dumas, L., Hieblot, C., Gilhodes, J., Cioci, G., Hugnot, J. P., Ameadan, A., Guillonneau, F., Dassi, E., Cammas, A., &Millevoi, S. (2021). Author Correction: hnRNP H/F drive RNA G-quadruplex-mediated translation linked to genomic instability and therapy resistance in glioblastoma (Nature Communications, (2020), 11, 1, (2661), 10.1038/s41467-020-16168-x). *Nature Communications*, *12*(1), 41467. https://doi.org/10.1038/s41467-021-23484-3

Hirono, S., Ozaki, K., Kobayashi, M., Hara, A., Yamaki, T., Matsutani, T., &Iwadate, Y. (2021). Oncological and functional outcomes of supratotal resection of IDH1 wild-type glioblastoma based on 11C-methionine PET: a retrospective, single-center study. *Scientific Reports*, *11*(1), 1–12. https://doi.org/10.1038/s41598-021-93986-z

Ho, C., Wang, C., Mattu, S., Destefanis, G., Ladu, S., Delogu, S., Armbruster, J., Fan, L., Lee, S. A., Jiang, L., Dombrowski, F., Evert, M., Chen, X., &Calvisi, D. F. (2012). AKT (v-akt murine thymoma viral oncogene homolog 1) and N-Ras (neuroblastomaras viral oncogene homolog) coactivation in the mouse liver promotes rapid carcinogenesis by way of mTOR (mammalian target of rapamycin complex 1), FOXM1 (forkhead box M1)/SKP2, . *Hepatology*, *55*(3), 833–845. https://doi.org/10.1002/hep.24736

Höland, K., Boller, D., Hagel, C., Dolski, S., Treszl, A., Pardo, O. E., Ćwiek, P., Salm, F., Leni, Z., Shepherd, P. R., Styp-Rekowska, B., Djonov, V., Von Bueren, A. O., Frei, K., & Arcaro, A. (2014). Targeting class Ia PI3K isoforms selectively impairs cell growth, survival, and migration in glioblastoma. *PLoS ONE*, *9*(4), 1–14. https://doi.org/10.1371/journal.pone.0094132

Holland, E. C., Celestino, J., Dai, C., Schaefer, L., Sawaya, R. E., & Fuller, G. N. (2000). Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice. *Nature Genetics*, *25*(1), 55–57. https://doi.org/10.1038/75596

Hu, L. S., Ning, S., Eschbacher, J. M., Baxter, L. C., Gaw, N., Ranjbar, S., Plasencia, J., Dueck, A. C., Peng, S., Smith, K. A., Nakaji, P., Karis, J. P., Quarles, C. C., Wu, T., Loftus, J. C., Jenkins, R. B., Sicotte, H., Kollmeyer, T. M., O'Neill, B. P., … Mitchell, J. R. (2017). Radiogenomics to

characterize regional genetic heterogeneity in glioblastoma. *Neuro-Oncology*, *19*(1), 128–137. https://doi.org/10.1093/neuonc/now135

Huang, H., Zhang, S., Li, Y., Liu, Z., Mi, L., Cai, Y., Wang, X., Chen, L., Ran, H., Xiao, D., Li, F., Wu, J., Li, T., Han, Q., Chen, L., Pan, X., Li, H., Li, T., He, K., … Man, J. (2021). Suppression of mitochondrial ROS by prohibitin drives glioblastoma progression and therapeutic resistance. *Nature Communications*, *12*(1), 1–16. https://doi.org/10.1038/s41467-021-24108-6

Huang, J. L., Jiang, G., Song, Q. X., Gu, X., Hu, M., Wang, X. L., Song, H. H., Chen, L. P., Lin, Y. Y., Jiang, D., Chen, J., Feng, J. F., Qiu, Y. M., Jiang, J. Y., Jiang, X. G., Chen, H. Z., & Gao, X. L. (2017). Lipoprotein-biomimetic nanostructure enables efficient targeting delivery of siRNA to Ras-activated glioblastoma cells via macropinocytosis. *Nature Communications*, *8*(May), 1–18. https://doi.org/10.1038/ncomms15144

Huang, P. H., Xu, A. M., & White, F. M. (2009). Oncogenic EGFR signaling networks in glioma. *Science Signaling*, *2*(87). https://doi.org/10.1126/scisignal.287re6

Itoh, N., &Ornitz, D. M. (2004). Evolution of the Fgf and Fgfr gene families. *Trends in Genetics*, *20*(11), 563–569. https://doi.org/10.1016/j.tig.2004.08.007

Iwanami, A., Gini, B., Zanca, C., Matsutani, T., Assuncao, A., Nael, A., Dang, J., Yang, H., Zhu, S., Kohyama, J., Kitabayashi, I., Cavenee, W. K., Cloughesy, T. F., Furnari, F. B., Nakamura, M., Toyam, Y., Okano, H., &Mischel, P. S. (2013). PML mediates glioblastoma resistance to mammalian target of rapamycin (mTOR)-targeted therapies. *Proceedings of the National Academy of Sciences of the United States of America*, *110*(11), 4339–4344. https://doi.org/10.1073/pnas.1217602110

Jamieson, S., Flanagan, J. U., Kolekar, S., Buchanan, C., Kendall, J. D., Lee, W. J., Rewcastle, G. W., Denny, W. A., Singh, R., Dickson, J., Baguley, B. C., & Shepherd, P. R. (2011). A drug targeting only p110α can block phosphoinositide 3-kinase signalling and tumour growth in certain cell types. *Biochemical Journal*, *438*(1), 53–62. https://doi.org/10.1042/BJ20110502

Jo, Y., Kim, E. H., Sai, S., Kim, J. S., Cho, J. M., Kim, H., Baek, J. H., Kim, J. Y., Hwang, S. G., & Yoon, M. (2018). Functional biological activity of sorafenib as a tumor-treating field sensitizer for glioblastoma therapy. *International Journal of Molecular Sciences*, *19*(11), 1–18. https://doi.org/10.3390/ijms19113684

Joensuu, H., Puputti, M., Sihto, H., Tynninen, O., &Nupponen, N. N. (2005). Amplification of genes encoding KIT, PDGFRα and VEGFR2 receptor tyrosine kinases is frequent in glioblastoma multiforme. *Journal of Pathology*, *207*(2), 224–231. https://doi.org/10.1002/path.1823

Johnson, K. C., Houseman, E. A., King, J. E., Von Herrmann, K. M., Fadul, C. E., & Christensen, B. C. (2016). 5-Hydroxymethylcytosine localizes to enhancer elements and is associated with survival in glioblastoma patients. *Nature Communications*, *7*, 1–11. https://doi.org/10.1038/ncomms13177

Jones, N. M., Rowe, M. R., Shepherd, P. R., & McConnell, M. J. (2016). Targeted inhibition of dominant PI3-kinase catalytic isoforms increase expression of stem cell genes in glioblastoma cancer stem cell models. *International Journal of Oncology*, *49*(1), 207–216. https://doi.org/10.3892/ijo.2016.3510

Joy, A., Kapoor, M., Georges, J., Butler, L., Chang, Y., Li, C., Crouch, A., Smirnov, I., Nakada, M., Hepler, J., Marty, M., & Feuerstein, B. G. (2016). The role of AKT isoforms in glioblastoma: AKT3 delays tumor progression. *Journal of Neuro-Oncology*, *130*(1), 43–52. https://doi.org/10.1007/s11060-016-2220-z

Kaley, T. J., Panageas, K. S., Mellinghoff, I. K., Nolan, C., Gavrilovic, I. T., DeAngelis, L. M., Abrey, L. E., Holland, E. C., &Lassman, A. B. (2019). Phase II trial of an AKT inhibitor (perifosine) for recurrent glioblastoma. *Journal of Neuro-Oncology*, *144*(2), 403–407. https://doi.org/10.1007/s11060-019-03243-7

kalhori, M. R., Arefian, E., FallahAtanaki, F., Kavousi, K., & Soleimani, M. (2020). miR-548x and miR-4698 controlled cell proliferation by affecting the PI3K/AKT signaling pathway in Glioblastoma cell lines. *Scientific Reports*, *10*(1), 1–12. https://doi.org/10.1038/s41598-020-57588-5

Kang, Y. J., Balter, B., Csizmadia, E., Haas, B., Sharma, H., Bronson, R., & Yan, C. T. (2017). Corrigendum: Contribution of classical end-joining to PTEN inactivation in p53-mediated glioblastoma formation and drug-resistant survival (Nature Communications, (2017), 8, 1, (14013), 10.1038/ncomms14013). *Nature Communications*, *8*(1), 1. https://doi.org/10.1038/ncomms15795

Keime-Guibert, F., Chinot, O., Taillandier, L., Cartalat-Carel, S., Frenay, M., Kantor, G., Guillamo, J.-S., Jadaud, E., Colin, P., Bondiau, P.-Y., Meneï, P., Loiseau, H., Bernier, V., Honnorat, J., Barrié, M., Mokhtari, K., Mazeron, J.-J., Bissery, A., & Delattre, J.-Y. (2007). Radiotherapy for Glioblastoma in the Elderly. *New England Journal of Medicine*, *356*(15), 1527–1535. https://doi.org/10.1056/nejmoa065901

Kim, J. H., Jeong, K., Li, J., Murphy, J. M., Vukadin, L., Stone, J. K., Richard, A., Tran, J., Gillespie, G. Y., Flemington, E. K., Sobol, R. W., Lim, S. T. S., &Ahn, E. Y. E. (2021). SON drives oncogenic

RNA splicing in glioblastoma by regulating PTBP1/PTBP2 switching and RBFOX2 activity. *Nature Communications*, *12*(1). https://doi.org/10.1038/s41467-021-25892-x

Koga, T., Maruyama, K., Tanaka, M., Ino, Y., Saito, N., Nakagawa, K., Shibahara, J., &Todo, T. (2012). Extended field stereotactic radiosurgery for recurrent glioblastoma. *Cancer*, *118*(17), 4193–4200. https://doi.org/10.1002/cncr.27372

Krauze, A. V., Myrehaug, S. D., Chang, M. G., Holdford, D. J., Smith, S., Shih, J., Tofilon, P. J., Fine, H. A., &Camphausen, K. (2015). A Phase 2 Study of Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients with Glioblastoma. *International Journal of Radiation Oncology Biology Physics*, *92*(5), 986–992. https://doi.org/10.1016/j.ijrobp.2015.04.038

Land, S. C., & Tee, A. R. (2007). Hypoxia-inducible factor 1α is regulated by the mammalian target of rapamycin (mTOR) via an mTOR signaling motif. *Journal of Biological Chemistry*, *282*(28), 20534–20543. https://doi.org/10.1074/jbc.M611782200

Lang, F. F., Conrad, C., Gomez-Manzano, C., Alfred Yung, W. K., Sawaya, R., Weinberg, J. S., Prabhu, S. S., Rao, G., Fuller, G. N., Aldape, K. D., Gumin, J., Vence, L. M., Wistuba, I., Rodriguez-Canales, J., Villalobos, P. A., Dirven, C. M. F., Tejada, S., Valle, R. D., Alonso, M. M., … Fueyo, J. (2018). Phase I study of DNX-2401 (delta-24-RGD) oncolytic adenovirus: replication and immunotherapeutic effects in recurrent malignant glioma. *Journal of Clinical Oncology*, *36*(14), 1419–1427. https://doi.org/10.1200/JCO.2017.75.8219

Lang, L. (2008). FDA Approves Sorafenib for Patients With Inoperable Liver Cancer. *Gastroenterology*, *134*(2), 379. https://doi.org/10.1053/j.gastro.2007.12.037

Laoukili, J., Stahl, M., &Medema, R. H. (2007). FoxM1: At the crossroads of ageing and cancer. *Biochimica et BiophysicaActa - Reviews on Cancer*, *1775*(1), 92–102. https://doi.org/10.1016/j.bbcan.2006.08.006

Larson, E. W., Peterson, H. E., Lamoreaux, W. T., MacKay, A. R., Fairbanks, R. K., Call, J. A., Carlson, J. D., Ling, B. C., Demakas, J. J., Cooke, B. S., & Lee, C. M. (2014). Clinical outcomes following salvage Gamma Knife radiosurgery for recurrent glioblastoma. *World Journal of Clinical Oncology*, *5*(2), 142–148. https://doi.org/10.5306/wjco.v5.i2.142

Lawrence, Y. R., Li, X. A., el Naqa, I., Hahn, C. A., Marks, L. B., Merchant, T. E., & Dicker, A. P. (2010). Radiation Dose-Volume Effects in the Brain. *International Journal of Radiation Oncology Biology Physics*, *76*(3 SUPPL.), 20–27. https://doi.org/10.1016/j.ijrobp.2009.02.091

Lefevre, M. C., Dijk, G., Kaszas, A., Baca, M., Moreau, D., & O'Connor, R. P. (2021). Integrating flexible electronics for pulsed electric field delivery in a vascularized 3D glioblastoma model. *Npj Flexible Electronics*, *5*(1), 1–9. https://doi.org/10.1038/s41528-021-00115-x

Li, H., Liu, S., Jin, R., Xu, H., Li, Y., & Chen, Y. (2021). Pyrvinium pamoate regulates MGMT expression through suppressing the Wnt / β -catenin signaling pathway to enhance the glioblastoma sensitivity to temozolomide. *Cell Death Discovery*, *September*. https://doi.org/10.1038/s41420-021-00654-2

Li, X., & Gao, T. (2014). MTORC2 phosphorylates protein kinase Cζ to regulate its stability and activity. *EMBO Reports*, *15*(2), 191–198. https://doi.org/10.1002/embr.201338119

Liang, Y., Li, Z., Yuan, H., Wang, L., & Gao, L. H. (2021). Poly(p-phenylenevinylene) nanoparticles modified with antiEGFRvIII for specific glioblastoma therapy. *Scientific Reports*, *11*(1), 1–8. https://doi.org/10.1038/s41598-021-83931-5

Lim, J. H., Lee, E. S., You, H. J., Lee, J. W., Park, J. W., & Chun, Y. S. (2004). Ras-dependent induction of HIF-1α785 via the Raf/MEK/ERK pathway: A novel mechanism of Ras-mediated tumor promotion. *Oncogene*, *23*(58), 9427–9431. https://doi.org/10.1038/sj.onc.1208003

Liu, E. K., Sulman, E. P., Wen, P. Y., & Kurz, S. C. (2020). Novel Therapies for Glioblastoma. *Current Neurology and Neuroscience Reports*, *20*(7). https://doi.org/10.1007/s11910-020-01042-6

Liu, H. L., Hua, M. Y., Chen, P. Y., Chu, P. C., Pan, C. H., Yang, H. W., Huang, C. Y., Wang, J. J., Yen, T. C., & Wei, K. C. (2010). Blood-brain barrier disruption with focused ultrasound enhances delivery of chemotherapeutic drugs for glioblastoma treatment. *Radiology*, *255*(2), 415–425. https://doi.org/10.1148/radiol.10090699

Liu, L. P., Ho, R. L. K., Chen, G. G., & Lai, P. B. S. (2012). Sorafenib inhibits hypoxia-inducible factor-1α synthesis: Implications for antiangiogenic activity in hepatocellular carcinoma. *Clinical Cancer Research*, *18*(20), 5662–5671. https://doi.org/10.1158/1078-0432.CCR-12-0552

Liu, X., Sun, K., Wang, H., & Dai, Y. (2016). Inhibition of Autophagy by Chloroquine Enhances the Antitumor Efficacy of Sorafenib in Glioblastoma. *Cellular and Molecular Neurobiology*, *36*(7), 1197–1208. https://doi.org/10.1007/s10571-015-0318-z

Lope, D., Ribalta, T., Ruano, Y., Garcı, J. F., Campos-martı, Y., & Pe, G. (2010). *N e u ro - o n co lo gy*. *12*(12), 1278–1290.

Lu, I. N., Dobersalske, C., Rauschenbach, L., Teuber-Hanselmann, S., Steinbach, A., Ullrich, V., Prasad, S., Blau, T., Kebir, S., Siveke, J. T., Becker, J. C., Sure, U., Glas, M., Scheffler, B., &Cima, I. (2021). Tumor-associated hematopoietic stem and progenitor cells positively linked to glioblastoma progression. *Nature Communications*, *12*(1). https://doi.org/10.1038/s41467-021-23995-z

Ma, R. Y. M., Tong, T. H. K., Cheung, A. M. S., Tsang, A. C. C., Leung, W. Y., & Yao, K. M. (2005). Raf/MEK/MAPK signaling stimulates the nuclear translocation and transactivating activity of FOXM1c. *Journal of Cell Science*, *118*(4), 795–806. https://doi.org/10.1242/jcs.01657

Maeyama, M., Tanaka, K., Nishihara, M., Irino, Y., Shinohara, M., Nagashima, H., Tanaka, H., Nakamizo, S., Hashiguchi, M., Fujita, Y., Kohta, M., Kohmura, E., & Sasayama, T. (2021). Metabolic changes and anti-tumor effects of a ketogenic diet combined with anti-angiogenic therapy in a glioblastoma mouse model. *Scientific Reports*, *11*(1), 1–11. https://doi.org/10.1038/s41598-020-79465-x

Maier, J. P., Ravi, V. M., Kueckelhaus, J., Behringer, S. P., Garrelfs, N., Will, P., Sun, N., von Ehr, J., Goeldner, J. M., Pfeifer, D., Follo, M., Hannibal, L., Walch, A. K., Hofmann, U. G., Beck, J., Heiland, D. H., Schnell, O., & Joseph, K. (2021). Inhibition of metabotropic glutamate receptor III facilitates sensitization to alkylating chemotherapeutics in glioblastoma. *Cell Death and Disease*, *12*(8). https://doi.org/10.1038/s41419-021-03937-9

Malmström, A., Grønberg, B. H., Marosi, C., Stupp, R., Frappaz, D., Schultz, H., Abacioglu, U., Tavelin, B., Lhermitte, B., Hegi, M. E., Rosell, J., &Henriksson, R. (2012). Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: The Nordic randomised, phase 3 trial. *The Lancet Oncology*, *13*(9), 916–926. https://doi.org/10.1016/S1470-2045(12)70265-6

Manning, B. D., &Cantley, L. C. (2007). AKT/PKB Signaling: Navigating Downstream. *Cell*, *129*(7), 1261–1274. https://doi.org/10.1016/j.cell.2007.06.009

Maxwell, R., Jackson, C. M., & Lim, M. (2017). Clinical Trials Investigating Immune Checkpoint Blockade in Glioblastoma. *Current Treatment Options in Oncology*, *18*(8). https://doi.org/10.1007/s11864-017-0492-y

McAvoy, M., Prieto, P. C., Kaczmarzyk, J. R., Fernández, I. S., McNulty, J., Smith, T., Yu, K. H., Gormley, W. B., & Arnaout, O. (2021). Classification of glioblastoma versus primary central nervous system lymphoma using convolutional neural networks. *Scientific Reports*, *11*(1), 1–7. https://doi.org/10.1038/s41598-021-94733-0

Memmott, R. M., & Dennis, P. A. (2009). Akt-dependent and -independent mechanisms of mTOR regulation in cancer. *Cellular Signalling*, *21*(5), 656–664. https://doi.org/10.1016/j.cellsig.2009.01.004

Mesic, A., Rogar, M., Hudler, P., Bilalovic, N., Eminovic, I., &Komel, R. (2021). Genetic variations in AURORA cell cycle kinases are associated with glioblastoma multiforme. *Scientific Reports*, *11*(1), 1–9. https://doi.org/10.1038/s41598-021-96935-y

Myatt, S. S., & Lam, E. W. F. (2007). The emerging roles of forkhead box (Fox) proteins in cancer. *Nature Reviews Cancer*, *7*(11), 847–859. https://doi.org/10.1038/nrc2223

Nguyen, T. T. T., Shang, E., Shu, C., Kim, S., Mela, A., Humala, N., Mahajan, A., Yang, H. W., Akman, H. O., Quinzii, C. M., Zhang, G., Westhoff, M. A., Karpel-Massler, G., Bruce, J. N., Canoll, P., &Siegelin, M. D. (2021). Aurora kinase A inhibition reverses the Warburg effect and elicits unique metabolic vulnerabilities in glioblastoma. *Nature Communications*, *12*(1), 1–19. https://doi.org/10.1038/s41467-021-25501-x

Obara, E. A. A., Aguilar-Morante, D., Rasmussen, R. D., Frias, A., Vitting-Serup, K., Lim, Y. C., Elbæk, K. J., Pedersen, H., Vardouli, L., Jensen, K. E., Skjoth-Rasmussen, J., Brennum, J., Tuckova, L., Strauss, R., Dinant, C., Bartek, J., &Hamerlik, P. (2020). SPT6-driven error-free DNA repair safeguards genomic stability of glioblastoma cancer stem-like cells. *Nature Communications*, *11*(1). https://doi.org/10.1038/s41467-020-18549-8

Parsa, A. T., Waldron, J. S., Panner, A., Crane, C. A., Parney, I. F., Barry, J. J., Cachola, K. E., Murray, J. C., Tihan, T., Jensen, M. C., Mischel, P. S., Stokoe, D., & Pieper, R. O. (2007). Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. *Nature Medicine*, *13*(1), 84–88. https://doi.org/10.1038/nm1517

Perry, J. R., Laperriere, N., O'Callaghan, C. J., Brandes, A. A., Menten, J., Phillips, C., Fay, M., Nishikawa, R., Cairncross, J. G., Roa, W., Osoba, D., Rossiter, J. P., Sahgal, A., Hirte, H., Laigle-Donadey, F., Franceschi, E., Chinot, O., Golfinopoulos, V., Fariselli, L., … Mason, W. P. (2017). Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma. *New England Journal of Medicine*, *376*(11), 1027–1037. https://doi.org/10.1056/nejmoa1611977

Phuphanich, S., Wheeler, C. J., Rudnick, J. D., Mazer, M., Wang, H., Nuño, M. A., Richardson, J. E., Fan, X., Ji, J., Chu, R. M., Bender, J. G., Hawkins, E. S., Patil, C. G., Black, K. L., & Yu, J. S. (2013). Phase i trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly

diagnosed glioblastoma. *Cancer Immunology, Immunotherapy*, *62*(1), 125–135. https://doi.org/10.1007/s00262-012-1319-0

Pibuel, M. A., Poodts, D., Díaz, M., Molinari, Y. A., Franco, P. G., Hajos, S. E., &Lompardía, S. L. (2021). Antitumor effect of 4MU on glioblastoma cells is mediated by senescence induction and CD44 , RHAMM and p-ERK modulation. *Cell Death Discovery*, *September*, 1–14. https://doi.org/10.1038/s41420-021-00672-0

Puli, S., Jain, A., Lai, J. C. K., & Bhushan, A. (2010). Effect of combination treatment of rapamycin and isoflavones on mtor pathway in human glioblastoma (U87) cells. *Neurochemical Research*, *35*(7), 986–993. https://doi.org/10.1007/s11064-010-0142-2

Rajani, K. R., Carlstrom, L. P., Parney, I. F., Johnson, A. J., Warrington, A. E., & Burns, T. C. (2019). Harnessing radiation biology to augment immunotherapy for glioblastoma. *Frontiers in Oncology*, *9*(FEB), 1–19. https://doi.org/10.3389/fonc.2018.00656

Ranieri, G., Gadaleta-Caldarola, G., Goffredo, V., Patruno, R., Mangia, A., Rizzo, A., L. Sciorsci, R., & D. Gadaleta, C. (2012). Sorafenib (BAY 43-9006) in Hepatocellular Carcinoma Patients: From Discovery to Clinical Development. *Current Medicinal Chemistry*, *19*(7), 938–944. https://doi.org/10.2174/092986712799320736

Rasmussen, R. D., Gajjar, M. K., Tuckova, L., Jensen, K. E., Maya-Mendoza, A., Holst, C. B., Møllgård, K., Rasmussen, J. S., Brennum, J., Bartek, J., Syrucek, M., Sedlakova, E., Andersen, K. K., Frederiksen, M. H., Bartek, J., &Hamerlik, P. (2018). Erratum to: BRCA1-regulated RRM2 expression protects glioblastoma cells from endogenous replication stress and promotes tumorigenicity (Nature Communications, (2016), 7, 1, (13398), 10.1038/ncomms13398). *Nature Communications*, *9*(1), 41467. https://doi.org/10.1038/s41467-018-07892-6

Reardon, D. A., Desjardins, A., Vredenburgh, J. J., O'Rourke, D. M., Tran, D. D., Fink, K. L., Nabors, L. B., Li, G., Bota, D. A., Lukas, R. V., Ashby, L. S., Paul Duic, J., Mrugala, M. M., Cruickshank, S., Vitale, L., He, Y., Green, J. A., Yellin, M. J., Turner, C. D., … Sampson, J. H. (2020). Rindopepimut with bevacizumab for patients with relapsed EGFRvIII-expressing glioblastoma (REACT): Results of a double-blind randomized phase II trial. *Clinical Cancer Research*, *26*(7), 1586–1594. https://doi.org/10.1158/1078-0432.CCR-18-1140

Reardon, D. A., Vredenburgh, J. J., Desjardins, A., Peters, K., Gururangan, S., Sampson, J. H., Marcello, J., Herndon, J. E., McLendon, R. E., Janney, D., Friedman, A. H., Bigner, D. D., & Friedman, H. S. (2011). Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: Results of a phase II study

of sorafenib plus daily temozolomide in adults with recurrent glioblastoma. *Journal of Neuro-Oncology*, *101*(1), 57–66. https://doi.org/10.1007/s11060-010-0217-6

Riviere, P., Goodman, A. M., Okamura, R., Barkauskas, D. A., Whitchurch, T. J., Lee, S., Khalid, N., Collier, R., Mareboina, M., Frampton, G. M., Fabrizio, D., Sharabi, A. B., Kato, S., &Kurzrock, R. (2020). High tumor mutational burden correlates with longer survival in immunotherapy-naïve patients with diverse cancers. *Molecular Cancer Therapeutics*, *19*(10), 2139–2145. https://doi.org/10.1158/1535-7163.MCT-20-0161

Romani, M., Pistillo, M. P., Carosio, R., Morabito, A., &Banelli, B. (2018). Immune Checkpoints and Innovative Therapies in Glioblastoma. *Frontiers in Oncology*, *8*(October), 1–8. https://doi.org/10.3389/fonc.2018.00464

Sabanci, P. A., Ergüven, M., Yazihan, N., Aktaş, E., Aras, Y., Civelek, E., Aydoseli, A., Imer, M., Gürtekin, M., &Bilir, A. (2014). Sorafenib and lithium chloride combination treatment shows promising synergistic effects in human glioblastoma multiforme cells in vitro but midkine is not implicated. *Neurological Research*, *36*(3), 189–197. https://doi.org/10.1179/1743132813Y.0000000283

Sachamitr, P., Ho, J. C., Ciamponi, F. E., Ba-Alawi, W., Coutinho, F. J., Guilhamon, P., Kushida, M. M., Cavalli, F. M. G., Lee, L., Rastegar, N., Vu, V., Sánchez-Osuna, M., Coulombe-Huntington, J., Kanshin, E., Whetstone, H., Durand, M., Thibault, P., Hart, K., Mangos, M., … Dirks, P. B. (2021). PRMT5 inhibition disrupts splicing and stemness in glioblastoma. *Nature Communications*, *12*(1), 1–17. https://doi.org/10.1038/s41467-021-21204-5

Sareddy, G. R., Kesanakurti, D., Kirti, P. B., & Babu, P. P. (2013). Nonsteroidal anti-inflammatory drugs diclofenac and celecoxib attenuates Wnt/β-Catenin/Tcf signaling pathway in human glioblastoma cells. *Neurochemical Research*, *38*(11), 2313–2322. https://doi.org/10.1007/s11064-013-1142-9

Scartoni, D., Amelio, D., Palumbo, P., Giacomelli, I., &Amichetti, M. (2020). Proton therapy re-irradiation preserves health-related quality of life in large recurrent glioblastoma. *Journal of Cancer Research and Clinical Oncology*, *146*(6), 1615–1622. https://doi.org/10.1007/s00432-020-03187-w

Schuster, A., Klein, E., Neirinckx, V., Knudsen, A. M., Fabian, C., Hau, A. C., Dieterle, M., Oudin, A., Nazarov, P. V., Golebiewska, A., Muller, A., Perez-Hernandez, D., Rodius, S., Dittmar, G., Bjerkvig, R., Herold-Mende, C., Klink, B., Kristensen, B. W., &Niclou, S. P. (2020). AN1-type zinc finger protein 3 (ZFAND3) is a transcriptional regulator that drives Glioblastoma invasion. *Nature Communications*, *11*(1). https://doi.org/10.1038/s41467-020-20029-y

Schuster, J., Lai, R. K., Recht, L. D., Reardon, D. A., Paleologos, N. A., Groves, M. D., Mrugala, M. M., Jensen, R., Baehring, J. M., Sloan, A., Archer, G. E., Bigner, D. D., Cruickshank, S., Green, J. A., Keler, T., Davis, T. A., Heimberger, A. B., & Sampson, J. H. (2015). A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: The ACT III study. *Neuro-Oncology*, *17*(6), 854–861. https://doi.org/10.1093/neuonc/nou348

Seliger, C., Genbrugge, E., Gorlia, T., Chinot, O., Stupp, R., Nabors, B., Weller, M., &Hau, P. (2020). Use of metformin and outcome of patients with newly diagnosed glioblastoma: Pooled analysis. *International Journal of Cancer*, *146*(3), 803–809. https://doi.org/10.1002/ijc.32337

Sengupta, S., Marrinan, J., Frishman, C., & Sampath, P. (2012). Impact of temozolomide on immune response during malignant glioma chemotherapy. *Clinical and Developmental Immunology*, *2012*. https://doi.org/10.1155/2012/831090

Shah, N., Hallur, P. M., Ganesh, R. A., Sonpatki, P., Naik, D., Chandrachari, K. P., Puchalski, R. B., &Chaubey, A. (2021). Gelatin methacrylate hydrogels culture model for glioblastoma cells enriches for mesenchymal-like state and models interactions with immune cells. *Scientific Reports*, *11*(1), 1–18. https://doi.org/10.1038/s41598-021-97059-z

Shaw, E., Scott, C., Souhami, L., Dinapoli, R., Kline, R., Loeffler, J., &Farnan, N. (2000). Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: Final report of RTOG protocol 90- 05. *International Journal of Radiation Oncology Biology Physics*, *47*(2), 291–298. https://doi.org/10.1016/S0360-3016(99)00507-6

Sheng, Z., Li, L., Zhu, L. J., Smith, T. W., Demers, A., Ross, A. H., Moser, R. P., & Green, M. R. (2010). A genome-wide RNA interference screen reveals an essential CREB3L2-ATF5-MCL1 survival pathway in malignant glioma with therapeutic implications. *Nature Medicine*, *16*(6), 671–677. https://doi.org/10.1038/nm.2158

Shiojima, I., & Walsh, K. (2002). Role of Akt signaling in vascular homeostasis and angiogenesis. *Circulation Research*, *90*(12), 1243–1250. https://doi.org/10.1161/01.RES.0000022200.71892.9F

Song, E., Mao, T., Dong, H., Boisserand, L. S. B., Antila, S., Bosenberg, M., Alitalo, K., Thomas, J. L., & Iwasaki, A. (2020). VEGF-C-driven lymphatic drainage enables immunosurveillance of brain tumours. *Nature*, *577*(7792), 689–694. https://doi.org/10.1038/s41586-019-1912-x

Sonoda, Y., Ozawa, T., Aldape, K. D., Deen, D. F., Berger, M. S., & Pieper, R. O. (2001). Akt pathway activation converts anaplastic astrocytoma to glioblastoma multiforme in a human astrocyte model of glioma. *Cancer Research*, *61*(18), 6674–6678.

Steelman, L. S., Abrams, S. L., Shelton, J. G., Chappell, W. H., Bäsecke, J., Stivala, F., Donia, M., Nicoletti, F., Libra, M., Martelli, A. M., &McCubrey, J. A. (2010). Dominant roles of the Raf/MEK/ERK pathway in cell cycle progression, prevention of apoptosis and sensitivity to chemotherapeutic drugs. *Cell Cycle*, *9*(8), 1629–1638. https://doi.org/10.4161/cc.9.8.11487

Steiniger, S. C. J., Kreuter, J., Khalansky, A. S., Skidan, I. N., Bobruskin, A. I., Smirnova, Z. S., Severin, S. E., Uhl, R., Kock, M., Geiger, K. D., &Gelperina, S. E. (2004). Chemotherapy of glioblastoma in rats using doxorubicin-loaded nanoparticles. *International Journal of Cancer*, *109*(5), 759–767. https://doi.org/10.1002/ijc.20048

Stupp, R., Hegi, M. E., Mason, W. P., van den Bent, M. J., Taphoorn, M. J., Janzer, R. C., Ludwin, S. K., Allgeier, A., Fisher, B., Belanger, K., Hau, P., Brandes, A. A., Gijtenbeek, J., Marosi, C., Vecht, C. J., Mokhtari, K., Wesseling, P., Villa, S., Eisenhauer, E., … Mirimanoff, R. O. (2009). Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. *The Lancet Oncology*, *10*(5), 459–466. https://doi.org/10.1016/S1470-2045(09)70025-7

Stupp, R., Taillibert, S., Kanner, A., Read, W., Steinberg, D. M., Lhermitte, B., Toms, S., Idbaih, A., Ahluwalia, M. S., Fink, K., Di Meco, F., Lieberman, F., Zhu, J. J., Stragliotto, G., Tran, D. D., Brem, S., Hottinger, A. F., Kirson, E. D., Lavy-Shahaf, G., … Ram, Z. (2017). Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma a randomized clinical trial. *JAMA - Journal of the American Medical Association*, *318*(23), 2306–2316. https://doi.org/10.1001/jama.2017.18718

Sturm, D., Witt, H., Hovestadt, V., Khuong-Quang, D. A., Jones, D. T. W., Konermann, C., Pfaff, E., Tönjes, M., Sill, M., Bender, S., Kool, M., Zapatka, M., Becker, N., Zucknick, M., Hielscher, T., Liu, X. Y., Fontebasso, A. M., Ryzhova, M., Albrecht, S., … Pfister, S. M. (2012). Hotspot Mutations in H3F3A and IDH1 Define Distinct Epigenetic and Biological Subgroups of Glioblastoma. *Cancer Cell*, *22*(4), 425–437. https://doi.org/10.1016/j.ccr.2012.08.024

SuryoRahmanto, A., Savov, V., Brunner, A., Bolin, S., Weishaupt, H., Malyukova, A., Rosén, G., Čančer, M., Hutter, S., Sundström, A., Kawauchi, D., Jones, D. T., Spruck, C., Taylor, M. D., Cho, Y., Pfister, S. M., Kool, M., Korshunov, A., Swartling, F. J., &Sangfelt, O. (2016). FBW7 suppression leads to SOX9 stabilization and increased malignancy in medulloblastoma. *The EMBO Journal*, *35*(20), 2192–2212. https://doi.org/10.15252/embj.201693889

Swartz, A. M., Li, Q. J., & Sampson, J. H. (2014). Rindopepimut: A promising immunotherapeutic for the treatment of glioblastoma multiforme. *Immunotherapy*, *6*(6), 679–690. https://doi.org/10.2217/imt.14.21

Taal, W., van der Rijt, C. C. D., Dinjens, W. N. M., SillevisSmitt, P. A. E., Wertenbroek, A. A. A. C. M., Bromberg, J. E. C., van Heuvel, I., Kros, J. M., & van den Bent, M. J. (2015). Treatment of large low-grade oligodendroglial tumors with upfront procarbazine, lomustine, and vincristine chemotherapy with long follow-up: a retrospective cohort study with growth kinetics. *Journal of Neuro-Oncology*, *121*(2), 365–372. https://doi.org/10.1007/s11060-014-1641-9

Tan, A. C., Ashley, D. M., López, G. Y., Malinzak, M., Friedman, H. S., &Khasraw, M. (2020). Management of glioblastoma: State of the art and future directions. *CA: A Cancer Journal for Clinicians*, *70*(4), 299–312. https://doi.org/10.3322/caac.21613

Tan, Y. M., Sangfelt, O., &Spruck, C. (2008). The Fbxw7/hCdc4 tumor suppressor in human cancer. *Cancer Letters*, *271*(1), 1–12. https://doi.org/10.1016/j.canlet.2008.04.036

Tan, Y., Raychaudhuri, P., & Costa, R. H. (2007). Chk2 Mediates Stabilization of the FoxM1 Transcription Factor To Stimulate Expression of DNA Repair Genes. *Molecular and Cellular Biology*, *27*(3), 1007–1016. https://doi.org/10.1128/mcb.01068-06

Tanaka, H., Hosoi, Y., Ishikawa, K., Yoshitake, J., Shibata, T., Uchida, K., Hashizume, H., Mizuno, M., Okazaki, Y., Toyokuni, S., Nakamura, K., Kajiyama, H., Kikkawa, F., & Hori, M. (2021). Low temperature plasma irradiation products of sodium lactate solution that induce cell death on U251SP glioblastoma cells were identified. *Scientific Reports*, *11*(1), 1–10. https://doi.org/10.1038/s41598-021-98020-w

Unteroberdörster, M., Herring, A., Bendix, I., Lückemann, L., Petschulat, J., Sure, U., Keyvani, K., Hetze, S., Schedlowski, M., &Hadamitzky, M. (2021). Neurobehavioral effects in rats with experimentally induced glioblastoma after treatment with the mTOR-inhibitor rapamycin. *Neuropharmacology*, *184*(November 2020). https://doi.org/10.1016/j.neuropharm.2020.108424

Verhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., Alexe, G., Lawrence, M., O'Kelly, M., Tamayo, P., Weir, B. A., Gabriel, S., Winckler, W., Gupta, S., Jakkula, L., … Hayes, D. N. (2010). Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1. *Cancer Cell*, *17*(1), 98–110. https://doi.org/10.1016/j.ccr.2009.12.020

Vidal, V., Gutierrez, O., Talamillo, A., Velasquez, C., & Fernandez-Luna, J. L. (2021). Glioblastoma invasion factor ODZ1 is induced by microenvironmental signals through activation of a Stat3-dependent transcriptional pathway. *Scientific Reports*, *11*(1), 1–11. https://doi.org/10.1038/s41598-021-95753-6

von Roemeling, C. A., Wang, Y., Qie, Y., Yuan, H., Zhao, H., Liu, X., Yang, Z., Yang, M., Deng, W., Bruno, K. A., Chan, C. K., Lee, A. S., Rosenfeld, S. S., Yun, K., Johnson, A. J., Mitchell, D. A., Jiang, W., & Kim, B. Y. S. (2020). Therapeutic modulation of phagocytosis in glioblastoma can activate both innate and adaptive antitumour immunity. *Nature Communications*, *11*(1), 1–12. https://doi.org/10.1038/s41467-020-15129-8

Walton, R. W., Brown, M. C., Sacco, M. T., &Gromeier, M. (2018). Engineered Oncolytic Poliovirus PVSRIPO Subverts MDA5-Dependent Innate Immune Responses in Cancer Cells. *Journal of Virology*, *92*(19). https://doi.org/10.1128/jvi.00879-18

Wang, I.-C., Chen, Y.-J., Hughes, D., Petrovic, V., Major, M. L., Park, H. J., Tan, Y., Ackerson, T., & Costa, R. H. (2005). Forkhead Box M1 Regulates the Transcriptional Network of Genes Essential for Mitotic Progression and Genes Encoding the SCF (Skp2-Cks1) Ubiquitin Ligase. *Molecular and Cellular Biology*, *25*(24), 10875–10894. https://doi.org/10.1128/mcb.25.24.10875-10894.2005

Wang, P., Zhao, L., Gong, S., Xiong, S., Wang, J., Zou, D., Pan, J., Deng, Y., Yan, Q., Wu, N., & Liao, B. (2021). HIF1α/HIF2α–Sox2/Klf4 promotes the malignant progression of glioblastoma via the EGFR–PI3K/AKT signalling pathway with positive feedback under hypoxia. *Cell Death and Disease*, *12*(4). https://doi.org/10.1038/s41419-021-03598-8

Wang, S. I., Puc, J., Li, J., Bruce, J. N., Cairns, P., Sidransky, D., & Parsons, R. (1997). Somatic Mutations of PTEN in Glioblastoma Multiforme Advances in Brief Somatic Mutations of PTEN in Glioblastoma Multiforme. *Cancer Research*, *57*, 4183–4186.

Wang, Z., Banerjee, S., Kong, D., Li, Y., & Sarkar, F. H. (2007). Down-regulation of Forkhead Box M1 transcription factor leads to the inhibition of invasion and angiogenesis of pancreatic cancer cells. *Cancer Research*, *67*(17), 8293–8300. https://doi.org/10.1158/0008-5472.CAN-07-1265

Wang, Z., Li, Y., Kong, D., Banerjee, S., Ahmad, A., Azmi, A. S., Ali, S., Abbruzzese, J. L., Gallick, G. E., &Sarkarr, F. H. (2009). Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. *Cancer Research*, *69*(6), 2400–2407. https://doi.org/10.1158/0008-5472.CAN-08-4312

Wei, L. H., Su, H., Hildebrandt, I. J., Phelps, M. E., Czernin, J., & Weber, W. A. (2008). Changes in tumor metabolism as readout for mammalian target of rapamycin kinase inhibition by rapamycin in glioblastoma. *Clinical Cancer Research*, *14*(11), 3416–3426. https://doi.org/10.1158/1078-0432.CCR-07-1824

Weller, M., Butowski, N., Tran, D. D., Recht, L. D., Lim, M., Hirte, H., Ashby, L., Mechtler, L., Goldlust, S. A., Iwamoto, F., Drappatz, J., O'Rourke, D. M., Wong, M., Hamilton, M. G., Finocchiaro, G., Perry, J., Wick, W., Green, J., He, Y., … Nag, S. (2017). Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. *The Lancet Oncology*, *18*(10), 1373–1385. https://doi.org/10.1016/S1470-2045(17)30517-X

Wen, Y. D., Zhu, X. S., Li, D. J., Zhao, Q., Cheng, Q., & Peng, Y. (2021). Proteomics-based prognostic signature and nomogram construction of hypoxia microenvironment on deteriorating glioblastoma (GBM) pathogenesis. *Scientific Reports*, *11*(1), 1–14. https://doi.org/10.1038/s41598-021-95980-x

Wenger, C., Salvador, R., Basser, P. J., & Miranda, P. C. (2015). The electric field distribution in the brain during TTFields therapy and its dependence on tissue dielectric properties and anatomy: A computational study. *Physics in Medicine and Biology*, *60*(18), 7339–7357. https://doi.org/10.1088/0031-9155/60/18/7339

Wick, A., Kessler, T., Elia, A. E. H., Winkler, F., Batchelor, T. T., Platten, M., & Wick, W. (2017). *Invited Review to Neuro Oncology Glioblastoma in the elderly: solid conclusions built on shifting sand?*

Wick, W., Platten, M., Meisner, C., Felsberg, J., Tabatabai, G., Simon, M., Nikkhah, G., Papsdorf, K., Steinbach, J. P., Sabel, M., Combs, S. E., Vesper, J., Braun, C., Meixensberger, J., Ketter, R., Mayer-Steinacker, R., Reifenberger, G., & Weller, M. (2012). Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: The NOA-08 randomised, phase 3 trial. *The Lancet Oncology*, *13*(7), 707–715. https://doi.org/10.1016/S1470-2045(12)70164-X

Wilhelm, S., Chien, D., & Lines, T. C. (2002). *BAY 43-9006 : Preclinical Data*. 2255–2257.

WINTER, A. J., SIMON, J., McNUTT, S. H., & CASIDA, L. E. (1960). The effect of an induced state of leukopenia on the uterine bactericical activity in rabbits. *American Journal of Veterinary Research*, *21*, 664–667.

Wu, J., Wang, N., Yang, Y., Jiang, G., Mu, Q., Zhan, H., & Li, F. (2021). Correction: LINC01152 upregulates MAML2 expression to modulate the progression of glioblastoma multiforme via Notch

signaling pathway (Cell Death & Disease, (2021), 12, 1, (115), 10.1038/s41419-020-03163-9). *Cell Death and Disease*, *12*(10), 2021. https://doi.org/10.1038/s41419-021-04106-8

Wu, Y., Fletcher, M., Gu, Z., Wang, Q., Costa, B., Bertoni, A., Man, K. H., Schlotter, M., Felsberg, J., Mangei, J., Barbus, M., Gaupel, A. C., Wang, W., Weiss, T., Eils, R., Weller, M., Liu, H., Reifenberger, G., Korshunov, A., … Radlwimmer, B. (2020). Glioblastoma epigenome profiling identifies SOX10 as a master regulator of molecular tumour subtype. *Nature Communications*, *11*(1). https://doi.org/10.1038/s41467-020-20225-w

Xie, R., Wu, Z., Zeng, F., Cai, H., Wang, D., Gu, L., Zhu, H., Lui, S., Guo, G., Song, B., Li, J., Wu, M., & Gong, Q. (2021). Retro-enantio isomer of angiopep-2 assists nanoprobes across the blood-brain barrier for targeted magnetic resonance/fluorescence imaging of glioblastoma. *Signal Transduction and Targeted Therapy*, *6*(1), 1–13. https://doi.org/10.1038/s41392-021-00724-y

Yang, F., Brown, C., Buettner, R., Hedvat, M., Starr, R., Scuto, A., Schroeder, A., Jensen, M., & Jove, R. (2010). Sorafenib induces growth arrest and apoptosis of human glioblastoma cells through the dephosphorylation of signal transducers and activators of transcription 3. *Molecular Cancer Therapeutics*, *9*(4), 953–962. https://doi.org/10.1158/1535-7163.MCT-09-0947

Yang, F., He, Z., Duan, H., Zhang, D., Li, J., Yang, H., Dorsey, J. F., Zou, W., Ali Nabavizadeh, S., Bagley, S. J., Abdullah, K., Brem, S., Zhang, L., Xu, X., Byrne, K. T., Vonderheide, R. H., Gong, Y., & Fan, Y. (2021). Synergistic immunotherapy of glioblastoma by dual targeting of IL-6 and CD40. *Nature Communications*, *12*(1), 1–15. https://doi.org/10.1038/s41467-021-23832-3

Yang, G., Murashige, D. S., Humphrey, S. J., & James, D. E. (2015). A Positive Feedback Loop between Akt and mTORC2 via SIN1 Phosphorylation. *Cell Reports*, *12*(6), 937–943. https://doi.org/10.1016/j.celrep.2015.07.016

Yang, R., Wang, M., Zhang, G., Bao, Y., Wu, Y., Li, X., Yang, W., & Cui, H. (2020). E2F7−EZH2 axis regulates PTEN/AKT/mTORsignalling and glioblastoma progression. *British Journal of Cancer*, *123*(9), 1445−1455. https://doi.org/10.1038/s41416-020-01032-y

Yang, R., Wang, M., Zhang, G., Li, Y., Wang, L., & Cui, H. (2021). POU2F2 regulates glycolytic reprogramming and glioblastoma progression via PDPK1-dependent activation of PI3K/AKT/mTOR pathway. *Cell Death and Disease*, *12*(5). https://doi.org/10.1038/s41419-021-03719-3

Yang, W.-B., Wu, A.-C., Hsu, T.-I., Liou, J.-P., Lo, W.-L., Chang, K.-Y., Chen, P.-Y., Kikkawa, U., Yang, S.-T., Kao, T.-J., Chen, R.-M., Chang, W.-C., Ko, C.-Y., & Chuang, J.-Y. (2021). Histone

deacetylase 6 acts upstream of DNA damage response activation to support the survival of glioblastoma cells. *Cell Death & Disease*, *12*(10). https://doi.org/10.1038/s41419-021-04182-w

Yang, Z. Z., Tschopp, O., Baudry, A., Dümmler, B., Hynx, D., & Hemmings, B. A. (2004). Physiological functions of protein kinase B/Akt. *Biochemical Society Transactions*, *32*(2), 350–354. https://doi.org/10.1042/BST0320350

Yee, P. P., Wei, Y., Kim, S. Y., Lu, T., Chih, S. Y., Lawson, C., Tang, M., Liu, Z., Anderson, B., Thamburaj, K., Young, M. M., Aregawi, D. G., Glantz, M. J., Zacharia, B. E., Specht, C. S., Wang, H. G., & Li, W. (2020). Neutrophil-induced ferroptosis promotes tumor necrosis in glioblastoma progression. *Nature Communications*, *11*(1), 1–22. https://doi.org/10.1038/s41467-020-19193-y

Yeini, E., Ofek, P., Pozzi, S., Albeck, N., Ben-Shushan, D., Tiram, G., Golan, S., Kleiner, R., Sheinin, R., Israeli Dangoor, S., Reich-Zeliger, S., Grossman, R., Ram, Z., Brem, H., Hyde, T. M., Magod, P., Friedmann-Morvinski, D., Madi, A., &Satchi-Fainaro, R. (2021). P-selectin axis plays a key role in microglia immunophenotype and glioblastoma progression. *Nature Communications*, *12*(1), 1–22. https://doi.org/10.1038/s41467-021-22186-0

Yu, C., Bruzek, L. M., Xue, W. M., Gores, G. J., Carter, C. A., Kaufmann, S. H., & Adjei, A. A. (2005). The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. *Oncogene*, *24*(46), 6861–6869. https://doi.org/10.1038/sj.onc.1208841

Yunoue, S., Tokuo, H., Fukunaga, K., Feng, L., Ozawa, T., Nishi, T., Kikuchi, A., Hattori, S., Kuratsu, J., Saya, H., & Araki, N. (2003). Neurofibromatosis type I tumor suppressor neurofibromin regulates neuronal differentiation via its GTPase-activating protein function toward Ras. *Journal of Biological Chemistry*, *278*(29), 26958–26969. https://doi.org/10.1074/jbc.M209413200

Zhai, B., Hu, F., Jiang, X., Xu, J., Zhao, D., Liu, B., Pan, S., Dong, X., Tan, G., Wei, Z., Qiao, H., Jiang, H., & Sun, X. (2014). Inhibition of akt reverses the acquired resistance to sorafenib by switching protective autophagy to autophagic cell death in hepatocellular carcinoma. *Molecular Cancer Therapeutics*, *13*(6), 1589–1598. https://doi.org/10.1158/1535-7163.MCT-13-1043

Zhang, C. Z., Wang, X. D., Wang, H. W., Cai, Y., & Chao, L. Q. (2015). Sorafenib inhibits liver cancer growth by decreasing MTOR, AKT, and PI3K expression. *Journal of B.U.ON.*, *20*(1), 218–222.

Zhang, Y., Zhang, N., Dai, B., Liu, M., Sawaya, R., Xie, K., & Huang, S. (2008). FoxM1B transcriptionally regulates vascular endothelial growth factor expression and promotes the angiogenesis and growth of glioma cells. *Cancer Research*, *68*(21), 8733–8742. https://doi.org/10.1158/0008-5472.CAN-08-1968

Zhang, Z., Li, X., Yang, F., Chen, C., Liu, P., Ren, Y., Sun, P., Wang, Z., You, Y., Zeng, Y.-X., & Li, X. (2021). DHHC9-mediated GLUT1 S-palmitoylation promotes glioblastoma glycolysis and tumorigenesis. *Nature Communications*, *12*(1), 1–12. https://doi.org/10.1038/s41467-021-26180-4

Zhao, H. F., Wang, J., Jiang, H. R., Chen, Z. P., & To, S. S. T. (2016). PI3K p110β isoform synergizes with JNK in the regulation of glioblastoma cell proliferation and migration through Akt and FAK inhibition. *Journal of Experimental and Clinical Cancer Research*, *35*(1), 1–14. https://doi.org/10.1186/s13046-016-0356-5

Zhu, G. dong, Yu, J., Sun, Z. yu, Chen, Y., Zheng, H. mei, Lin, M. lan, Ou-yang, S., Liu, G. long, Zhang, J. wen, & Shao, F. min. (2021). Genome-wide CRISPR/Cas9 screening identifies CARHSP1 responsible for radiation resistance in glioblastoma. *Cell Death and Disease*, *12*(8), 1–9. https://doi.org/10.1038/s41419-021-04000-3